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The rapid evolution of omics technologies for profiling the human genome, 
transcriptome and proteome is revolutionizing cancer research and driving a 
paradigm shift in clinical care. Omics have forever changed our view of cancer, 
from a uniform disease to a highly heterogeneous ecosystem of diseases driven 
by different genetic events. Standard care is, as well, evolving from “one size” fits 
all treatments towards more precise and molecularly informed therapies. The 
success of this precision medicine paradigm will depend on our ability to 
integrate diverse omics measurements to distill clinically relevant information that 
can be act upon. This thesis developed bioinformatics approaches to integrate 
multi-omics datasets and applied these approaches in three distinct studies that 
identified novel actionable genes and pathways in cancers.  
 
In the first study, we aim at finding alternative target proteins in cancer 
samples that share activating mutations in KRAS a well-known, but undruggable, 
oncogene. We profile the transcriptome, proteome and phosphoproteome in a 
panel of non-small cell lung cancer (NSCLC) cell lines in order to reconstruct 
targetable networks associated with KRAS dependency. A bioinformatics 
strategy was developed addressing the challenge of integrating these disparate 
datasets and the Prize Collecting Steiner Tree algorithm was used to identify 
functional sub-networks. Three modules centered on KRAS and MET, LCK and 
PAK1 and -Catenin were identified. We validated activation of these proteins in 
KRAS-dependent cells and performed functional studies defining LCK as a 
critical gene for cell proliferation in KRAS-dependent but not KRAS-independent 
NSCLCs. These results are the first evidence that suggest LCK as a potential 





In the second study, the landscape of fusions in lung adenocarcinoma and 
lung squamous carcinoma tissue types was described in order to identify 
potentially oncogenic gene fusions in driver negative patients. The landscape 
was found to be highly heterogeneous and gene fusions incidence was 
discovered to be an independent prognostic factor for poor outcome. By 
integrating gene mutation status, the lung cohort was divided into driver positive 
and driver negative patients (who do not have mutations in known cancer genes). 
Focusing in driver negative patients we identify NRG1 as a novel low recurrence 
3’ fusion partner present exclusively in this subset; resembling previously 
reported kinase fusions. The documented success of targeted therapies against 
low recurrence oncogenic fusions in lung cancer and the high heterogeneity of 
the fusions’ landscape, shown in this study, reinforce the demand for more 
personalized and tailored drug therapies.  
 
Finally in the third study, the landscape of antisense expression in human 
cancers was characterized in order to identify sense-antisense gene pairs 
involving tumor suppressors and oncogenes, which could be suitable for 
emerging antisense-targeted therapies. More than 60% of DNA loci were found 
to have measurable antisense transcription. Expression of sense and antisense 
transcript pairs is in general positively correlated and directed by bidirectional 
promoters in cases of overlapping divergent genes. By comparing with known 
sense-antisense pairs, our results raise the possibility that antisense transcripts 
could be regulating the expression of well-known tumor suppressors and 
oncogenes. This study provides a resource, oncoNATdb, a catalogue of cancer 
related genes with significant antisense transcription, which will allow cancer 
researchers to investigate the mechanisms of sense-antisense regulation and 




We anticipate that the computational methods developed and the results 
found in this thesis would assist others with similar tasks and warrant further 






Chapter 1  
Multi-omics data integration 
 
 
1.1 Background and significance 
 
The collective characterization and quantification of pools of biological 
molecules such as genes, transcripts and proteins have emerged as the 
complete new fields of genomics, transcriptomics and proteomics. Collectively, 
these and others high-throughput fields are known as Omics.  
 
Omics technologies for high-throughput profiling of the human genome, 
transcriptome and proteome are revolutionizing cancer research and driving a 
paradigm shift on clinical care. Omics have forever changed our view of cancer, 
from a uniform disease to a highly heterogeneous ecosystem of diseases driven 
by different genetic events. Standard care is, as well, evolving from “one size” fits 
all treatments towards more precise and molecularly informed therapies. This 
precision medicine paradigm depends on our ability for integrating diverse omics 
measurements to distill clinically relevant information that can be act upon. This 
dissertation focuses on developing bioinformatics approaches to integrate multi-
omics datasets to identify novel actionable genes and pathways in cancer. In 
three independent studies we integrate multi-omics cancer data in order to 
reconstruct novel targetable pathways in KRAS dependent lung cancer, search 
for novel oncogenic fusions in lung cancer patients with no known driver genes 
and study sense/antisense gene regulation in cancer. Our results warrant further 






1.2 Molecular characterization of lung cancers  
 
Lung cancer is the leading cause of cancer mortality in the world with 
more than one million deaths a year1. Non-small cell lung cancer (NSCLC) is the 
most predominant type of this malignancy, and it can be subdivided into lung 
adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC).  
 
Recent genomic analyses have deepened our understanding of the 
genetic alterations characterizing both LUAD and LUSC, and have revealed very 
different mutation landscapes. LUAD are mutated in several well-characterized 
oncogenes and tumor suppressor genes including KRAS (~30%), EGFR (~14%), 
BRAF (~10%), TP53 (~46%), and STK11 (~17%) among others2. Importantly, 
activating mutations in KRAS are mutually exclusive with activating mutations in 
EGFR. On the other hand, LUSC is characterized by mutations in TP53 (~81%), 
CDKN2A (15%), PTEN (8%), PIK3CA (16%), DDR2, AKT1, MLL2, NOTCH1, and 
RB1 as well as several recurrent gene copy number alterations of FGFR1, SOX2 
and TP633. This molecular heterogeneity underlies the difficulties in effectively 
treating patients with this disease. 
 
Remarkably, despite this deep molecular characterization of lung cancer, 
there is still above 30% of patients with no known driver genes. This driver 
negative subpopulation has been recently subject to intense study and additional 
driver events such as oncogenic gene fusions have been discovered.  
 
Several important gene fusions occur in lung cancer including the EML4-
ALK fusion gene identified in approximately 4% of adenocarcinomas4. This fusion 
protein links the N-terminal portion of echinoderm microtubule-associated 
protein-like 4 (EML4) with the intracellular signaling portion of the anaplastic 





mutually exclusive with EGFR and KRAS5. Additional gene fusions have now 
been identified in LUAD involving ROS1 6, as well as RET 7,8 kinases as 3’ 
partner genes.  
 
1.2.1 KRAS mutations lung cancers 
 
As mentioned above, mutations in the Ras oncogenes characterize 30-
40% of all NSCLC, with KRAS, NRAS, and HRAS being somatically mutated in 
30%, 1-5%, and 1% of the cases respectively 9. Recent studies suggest that a 
subset of KRAS mutant tumors are dependent on KRAS for survival10, implying 
that targeting KRAS or other genes downstream in this signaling cascade could 
yield potential drug targets to treat NSCLC. 
 
Ras is a GTP binding protein that communicates signaling information 
through five major cancer related pathways: Akt/PI3K, Raf –MAPK, RalGDS, 
phospholipase-Ce, and Rac 11. Mutations on residues 12, 13 and 61 in the 
GTPase pocket disrupt Ras GTPase activity generating constitutively active Ras 
proteins, which in turn affect transcription of numerous genes promoting cell 
proliferation and survival. Microarray profiling has been extensively used for 
defining gene expression signatures characterizing Ras activity in cell lines and 
tissues10,12,13 but results are inconsistent across studies. Complicating this 
matter, it has been shown that NSCLC can be subdivided into KRAS-dependent 
(KRAS-Dep) and KRAS-independent (KRAS-Ind) according to their requirement 
of KRAS for survival10,14; and more importantly KRAS pathway activity predicts 
KRAS dependency and drug resistance better than mutation status12.  
 
The active KRAS signaling pathway transmits information in the form of 
post-translational modification such as phosphorylation. Although previous 
studies have used semi or quantitative phospho-proteomics experiments to 





gene expression, protein abundance and protein phosphorylation status6,15-19,  as 
we have accomplished in chapter 2, missing the key opportunity of synthesizing 
all these levels of information.  
 
1.2.2 Targeted therapies 
 
Lung cancer patients whose tumors harbor EGFR activating mutations 
show responsiveness to drugs inhibitors such as Erlotinib and Gefitinib that 
target these particular alterations20.  More importantly, the presence of the ALK 
fusions is an indicator of therapeutic responsiveness to ALK inhibitors such as 
Crizotinib4. These results have accelerated the development of new drug 
inhibitors targeting additional genetic aberrations such as ROS1 and RET fusions 
and mutations in FGFR and PI3KCA among others.  
 
Remarkably, however, it is the absence of therapeutic options for treating 
the two biggest groups of lung cancers: patients with mutations in KRAS and 
driver negative patients.  
 
1.2.3 Drug therapies targeting Ras pathways 
 
The development of drug therapies aimed at disrupting Ras activity or 
blocking Ras pathways has proved challenging9. However, Ras driven tumors 
could harbor vulnerabilities in other pathways due to proteins which are not 
oncogenic themselves but are required for Ras dependency21. Therefore, 
inhibitors targeting various Ras effectors could be indirectly effective in treating 
tumors driven by Ras activity22. RNAi profiling studies aiming at identifying genes 
whose inhibition constitutes synthetic lethality with KRAS have identified 
vulnerable points in networks as diverse as the mitotic21,  the epithelial 
differentiation10 and NF-kB pathways14. Each study reported a different but not 





were detected in the Akt/PI3K and Raf –MAPK pathways neither in NSCLC cell 
lines10,14 nor in the KRAS dependent DLD-1 colorectal cell line21, indicating that 
other poorly characterized pathways may be contributing to the KRAS-induced 
oncogenic state. 
 
1.3 Omics Technologies 
 
Second generation sequencing, or next generation sequencing (NGS) as 
was initially named, allows researchers to sequence billions of DNA strands in 
parallel generating substantially more high throughput than conventional Sanger 
sequencing. Although recently developed, NGS technologies are being applied in 
a variety of fields ranging from gene mutation profiling, gene fusions detection, 
novel transcripts discovery, transcript expression, ribosome profiling and nascent 
RNA characterization to mention just a few. Through this dissertation we have 
primarily used DNA exome sequencing (ExomeSeq), RNA sequencing 
(RNASeq) and strand-specific RNA sequencing (ssRNASeq). 
 
1.3.1 DNA Sequencing 
 
In 2008 the first whole cancer genome was sequenced using NGS and 
since then several more genomes have been sequenced as part of The Cancer 
Genome Atlas project (TCGA). Although very useful for detecting large 
chromosomal rearrangements and somatic mutations of non-coding regions 
including promoters, enhancers and un-annotated regions the cost of sequencing 
the whole genome is still high enough to prevent its implementation on a routine 
basis. Exome sequencing, or targeted NGS of the coding regions of the genome 
is a more cost effective approach to reliably detect somatic mutations in the 
regions of interest due to increased sequence coverage gained by concentrating 





maximum sequence coverage of about 30x seen for whole genome sequencing, 
ExomeSeq can typically deliver greater than 100x over the targeted regions. 
 
1.3.2 RNA sequencing 
 
NGS of the transcriptome, or RNASeq, has been used to profile mRNA, 
total RNA and small RNAs in cancer and normal samples. RNASeq allows 
transcript quantification, transcript discovery and detection of in-frame oncogenic 
gene fusions, as well as alternative splice variants. RNASeq can also be used to 
detect somatic mutations; however, determining this without matched normal is 
challenging because normal tissues should not express the same gene repertoire 
as cancers. Moreover, gene expression level and infrequent mechanisms, such 
as RNA editing, need to be taken into account when using RNASeq for somatic 
mutation calling. Despite these challenges, several studies have properly used 
RNASeq to determine somatic mutations, cleverly restricting the analysis to well-
known mutations in cancer genes23. 
 
1.3.3 Strand specific RNA sequencing 
 
Standard RNASeq does not preserve information about which DNA strand 
was originally transcribed. In this method double stranded cDNA is randomly 
primed followed by addition of adaptors for NGS. In this process the information 
about what strand was present in the original mRNA template is lost. Strand 
information can improve the value of RNASeq experiments by providing accurate 
information about antisense transcripts, helping to clearly delimit gene 
boundaries of adjacent genes and to correctly resolve the expression levels of 
overlapping transcripts. 
 
Although many methods have been developed for generating strand 





predetermined orientation to ends of the RNAs molecules, direct sequencing of 
the first-strand cDNA products, or selective marking of the second-strand cDNA 
and subsequent degradation of the first-strand cDNA. Selective labeling is 
accomplished by using dUTP during cDNA synthesis or by bisulfite conversion of 
cytosine to uracil in RNA. Levin et al., 201024 compared the performance of 
seven ssRNASeq protocols and observed differences with respect to their level 
of strand specificity, evenness of coverage, agreement with known annotations, 
library complexity and the ability to generate quantitative expression profiles. 
They identified the dUTP labeling methods and Illumina RNA adaptor-ligation 
methods as the leading protocols, with dUTP libraries providing the additional 





Proteomics high-throughput methods, for profiling the abundance and 
post-translational modifications of proteins, is providing deep insights about the 
proteome organization of normal and cancer tissues25.  
 
In particular quantitative phospho-proteomics, label or label-free, allows 
researchers to characterize signaling pathways15-17. A general pipeline for label-
free phospho-proteome quantification is summarized in the following steps26-41: 
tryptic sample preparation, phospho-peptide enrichment, label-free quantitative 
tandem mass spectrometry, peptide identification through database search, and 
quantification. It is important to note that phospho-peptide enrichment is 
necessary because phospho-peptides correspond to a small fraction of all 
peptides obtained after tryptic digestion. Several enrichment methods have been 
proposed 36, such as immobilized metal affinity chromatography (IMAC), Titanium 
or Zirconium dioxide (TiO2, ZrO2) and phosphoamidate chemistry (PAC), which 





are typically under-represented with respect to phospho-Ser/Thr peptides, but 
they play an important role upstream and downstream of many signaling 
cascades. Finally, peptides and phospho-peptides are quantified by label or 
label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
 
Improvements in LC-MS/MS mass spectrometers are increasing the 
coverage of the proteome that is achieved in a single experiment to above 
10,000 proteins 43. Continuous improvements on the mass spectrometers 
resolution will close the gap between the number of transcripts identified by 
RNASeq experiments and the number of proteins identified by LC-MS/MS, 
allowing for better comparisons between the transcriptome and proteome of 
matched samples. 
 
1.4 Software used for data processing 
 
In order to organize the following sections, the data levels schema 
proposed by TCGA consortium1 was adopted. There are four data levels: Level 1 
(for Raw Data), Level 2 (for Processed Data), Level 3 (for Segmented or 
Interpreted Data) and Level 4 (for Summary or Region of Interest Data).  Table 
1.1-1 below describes the data levels with examples. The aims of this 
dissertation focus primarily on integration of level 3 and 4 datasets; however, a 
significant amount of work was devoted to generate bioinformatics pipelines for 
processing raw data from level 1 to level 3 for hundreds of samples.  A great deal 
of expertise on the computational tools for cancer genomics was gained through 
this process.  A list of computational tools for processing next generation 









































Data level Level type Description Example 
1 Raw 






Normalized single sample data 
Interpreted for presence 








Aggregate of processed data 
from single sample 
Gene expression 




Quantified association across 













Table 1.1-2. Computational tools for cancer genomics and proteomics.   
 
Category Method Comments Refs 
Alignment 
 
BWA Genome and exome alignment 44 
Bowtie/Bowtie2 Transcriptome alignment 45, 46 
ELAND Transcriptome and genome alignment  
TopHat2 Transcriptome alignment  47 
Mutation 
Calling 
VarScan2 Germline and somatic mutation calling 48 
GATK Germline and somatic mutation calling 49 
Samtools SNV mutation calling 50 
Gene 
Expression 
Cufflinks Gene expression quantification, FPKM 51 
Samtools Gene expression quantification, read counts 50 




DESeq Negative binomial and variance estimation 52 
Cufflinks Differential expression analysis 53 
EdgeR Negative binomial and variance estimation 54 
Fusion 
Calling 
TopHat-Fusion Fusion discovery from pair end sequencing 55 
ChimeraScan Fusion discovery from pair end sequencing 56 
Defuse Fusion discovery from pair end sequencing 57 
Proteomics 








1.5 Integration of omics datasets 
 
The term data integration is used in different contexts and does not always 
have the same meaning. The term is often employed to describe tools, methods 
and software used to interrogate different data sources such as databases or 
federate data repositories. The term is also utilized when combining related 
studies in order to obtain stronger conclusions or to increase the power of 
previous studies by collecting more data of the same type. Finally, the term is 
used when combining diverse and heterogeneous data types, measured in the 
same individual, in order to improve our understanding of a biological process or 
to uncover previously unappreciated relationships or measurements. Throughout 
this dissertation we will use the term data integration referring to the second and 
third examples described above. 
 
Genomics, transcriptomics, proteomics and epigenomics, to mention just a 
few of the omics platforms, each provides a one dimensional view of the cell 
components; integrative analysis promises a global and systemic view of these 
levels and their interactions. However, the huge amount of information obtained 
from each of these omics technologies and diversity in the platforms discussed 
above pose multiple bioinformatics challenges for data processing and 
combination.  
Despite these challenges collaborative projects such as the Encode 
project (ENCODE) and The Cancer Genome Atlas project (TCGA) are 
generating vast muti-omics datasets. The Encode project has deepened our 
understanding of gene elements and gene regulation, while TCGA is providing a 
full characterization of more than 25 different cancer types. These efforts 
highlight the importance and challenges of multi-omics data integration60. 
 
There are numerous methods for integrating omics datasets. This diversity 
is explained by the fact that the types of data integration used in a particular 





however, algorithms for multi-omics data integration usually belong to one of few 
categories: data reduction supervised algorithms and unsupervised algorithms. 
 
1.5.1 Data reduction 
 
In omics projects data reduction happens at several levels. For example, 
in RNASeq and ChipSeq the first step of data processing is to reduce the million 
of reads produced by the sequencing machine to a few hundreds or thousands of 
points (integers) representing the amount of those reads over a genomic interval. 
Then, a popular method of data integration is to perform intersection analysis 
between those genomic intervals and other regions from the same or different 
experiment, such as ChIPSeq peaks indicating specific chromatin marks. 
 
In a second level of data integration, data reduction statistical methods 
such as principal component analysis, multiple factor analysis and non-negative 
matrix factorization61,62 aim at reducing or transforming the variable space into 
one that represents the stronger tendencies in the data. Importantly, these 
methods are individually applied to each data set and then the results are 
combined. When applied to the full multi-omics datasets these methods usually 
depend on a strong correlation between the genomic levels, which are being 
combined. For example the positive correlation observed between the number of 
copies of a gene and its transcription level has been exploited for several 
methods to integrate copy number changes profiles (CNVs) with gene expression 
profiles63,64. 
 
1.5.2 Unsupervised data integration 
 
In unsupervised learning the goal is to summarize a large dataset into 
smaller groups that can be easily understood. The methods in this category 





dataset?” An assumption to have in mind when applying these methods is that 
the patterns that are discovered are usually the ones that appear more 
frequently, and therefore outlier events would not be identified despite their 
potential importance. An important caveat of these methods is that they will 
always find a pattern in the data regardless of its biological significance.  
 
Similarly to data reduction methods a standard approach with these 
unsupervised, or clustering, methods is to first find clusters in each data set and 
then map clusters between data types. The mapping procedure is not 
unsupervised and usually constitutes the most demanding part, for example 
clusters found at the gene expression level, representing co-expressed genes, 
are analyzed in light of clusters found in the chromatin level, representing co-
regulated loci. Because clustering methods are agnostic, as long as “pattern 
frequency” represents genes/proteins activity, they can be used, in principle, for 
summarizing multiple omics datasets at once as long as the data are properly 
normalized in advance and a strong correlation exists between data types65.  
 
1.5.3 Limitations of data reduction and unsupervised methods 
 
As described above statistical data reduction techniques and 
unsupervised clustering algorithms depended on strong correlation between data 
types in order to be useful in multi-omics integration tasks. This degree of 
correlation has been shown for example, between gene copy number and gene 
expression and activating chromatin marks and gene expression.  
 
However, this degree of correlation between omics datasets is not the 
norm and it is, indeed, not expected when integrating somatic mutations and 
gene expression, mRNA and protein abundance, or mRNA levels and 
phosphorylation status. In these cases the degree of correlation observed is 





Mutations abolishing gene expression, unstable mRNAs that are not correlated 
with protein abundance level, and proteins with constant abundance, but 
differential levels of phosphorylation, are some examples. The lack of correlation 
in those contexts is therefore not only due to noise but also due to the biological 
phenomena that are being studied.  
 
Another challenge when integrating heterogeneous omics datasets is the 
wide level of coverage between different technologies.  For example, a single 
RNASeq experiment can identify above 20,000 expressed transcripts, while a 
very good proteomics experiment will identify at the most 10,000 proteins. 
Similarly, the number of genes harboring somatic non-synonymous mutations in 
a sample is typically less than a 1000, and usually closer to 100. The number of 
phospho-proteins detected varies greatly depending on the enrichment protocol 
and LC-MS/MS mass spectrometer instrument used. This wide range of 
coverage generated by different omics platforms creates a high number of 
missing values and sparsity. The high number of missing values impedes the use 
of data reduction methods such as standard principal component analysis. 
 
1.6 Network biology approaches to data integration 
 
Another approach to multi-omics-based data integration is network 
biology. This approach leverages our current knowledge about the systemic 
relationships between the different components; such as, genes, proteins, and 
their interactions, and at the same time find new relationships in the data. 
Molecular pathways and protein-to-protein interactions are typical 
representations of our current knowledge about the molecular interactions in the 
cell.  
 
Network biology approaches address the challenges imposed by the low 





range of different omics platforms, by using the pathways or networks as 
common frameworks over which the information obtained from different omics-
based measurements is combined.  Overlaying different omics measurements on 
top biological networks brings functional information in order to make sense of 
the information gained through a multi-omics-based experiment. These 
approaches, are, therefore, becoming a common strategy for multi-omics data 
analysis.  
 
1.6.1 Network reconstruction 
 
Identification of pathways, modules, or functional sub-networks is a central 
theme in understanding oncogenesis from an integrative perspective, as well as 
a very challenging computational problem66. However, multi-omics data 
integration has been successful in building more complete models of cancer 
molecular networks29,67-80. 
Numerous computational methods are being proposed to identify 
functional and/or differential expressed modules68,77-79,81-94. Those methods can 
be sub-divided into two main different approaches according to their use of a 
priori information regarding the network of interactions. Inference methods that 
do not use a priori information require vast amounts of data in order to estimate 
their model’s parameters, which make them inappropriate for small datasets with 
few conditions. Methods that use a priori information depend on the quality and 
extent of this information. Fortunately, our knowledge of biological pathways and 
interactions is increasing constantly and pathway models can be refined and 
updated as needed. The focus of this dissertation is on the second type of 
methods, but a detailed comparison of both can be found elsewhere95. Within 
methods that use a priori information, methods proposed so far aim at finding a 
dense connected sub-network, based on a pre-specified protein-to-protein 





are treated as a snapshot of the dynamic behavior of the system, while the PPI, 
although incomplete, represents the universe of potential interactions.  
From a computational point of view, extracting functional sub-modules 
from high throughput omics-based data can be formulated as an optimization 
problem whose objective function is defined according to specific requirements. 
There are two types of module extraction methods heuristic and exact90. 
Heuristic methods were used to find cancer modules that distinguish breast 
cancer subtypes78 and to organize the Reactome database into pathways81. 
Heuristic approaches cannot guarantee the optimality of their solutions, whereas 
‘exact’ methods do so. Exact methods commonly employ integer or mixed-
integer linear programming techniques in order to find optimal solutions to the 
network extraction problem84,91,96. Among exact approaches, the Prize Collecting 
Steiner Tree (PCST) formulation has been successfully applied to find functional 
sub-networks in yeast and cancer77,842. In the second chapter of this dissertation 
the problem of integrating NSCLC transcriptome, proteome and phospho-
proteome datasets will be formulated as Prize Collecting Steiner Tree Problem, 
which solutions allow us to reconstruct active networks in KRAS dependent cells.  
 
1.7 Aims and structure of this thesis 
 
This dissertation focuses on developing bioinformatics approaches to 
integrate multi-omics datasets. As emphasized through this first chapter, data 
integration itself is designed to generate novel hypothesis that can be 
experimentally or computationally tested in order to answer specific scientific 
questions. The bioinformatics approaches developed in this thesis are all aimed 
at identifying novel actionable genes and pathways in cancer. These approaches 
were applied to find novel targets in three distinct scenarios, representing 
different cancer patient populations with unmet therapeutic needs.  
                                            






In the first study, we aim at finding alternative target proteins in cancer 
samples sharing activating mutations in KRAS a well known, but undruggable, 
oncogene. We profile the transcriptome, proteome and phosphoproteome in a 
panel of non-small cell lung cancer (NSCLC) cell lines in order to reconstruct 
targetable networks associated with KRAS dependency. We develop a 
bioinformatics strategy addressing the challenge of integrating these disparate 
datasets and use the Prize Collecting Steiner Tree algorithm to identify functional 
sub-networks. We identify three modules centered on KRAS and MET, LCK and 
PAK1 and -Catenin. We validate activation of these proteins in KRAS-
dependent cells and perform functional studies defining LCK as a critical gene for 
cell proliferation in KRAS-dependent but not KRAS-independent NSCLCs. These 
results are the first evidence to suggest LCK as a potential druggable target 
protein in KRAS-dependent lung cancers. 
In the second study, we describe the fusions landscape of lung 
adenocarcinoma and lung squamous carcinoma tissue types in order to identify 
potentially oncogenic gene fusions in driver negative patients. We show the high 
heterogeneity of this landscape and discover that gene fusions incidence is an 
independent prognostic factor for poor outcome. By integrating gene mutation 
status, we divide the cohort into driver positive and driver negative patients, who 
do not have mutations in known cancer genes. Focusing in driver negative 
patients we identify NRG1 as a novel low recurrence 3’ fusion partner present 
exclusively in this subset; resembling previously reported receptor kinase 
fusions. The documented success of targeted therapies against low recurrence 
oncogenic fusions in lung cancer and the high heterogeneity of the fusions’ 
landscape, shown in this study, reinforce the demand for more personalized and 
tailored drug therapies.  
Finally in the third study, we characterize the landscape of antisense 
expression in human cancers in order to identify sense-antisense gene pairs 
involving cancer related genes, which could be suitable for emerging antisense 





transcription and that the expression of sense and antisense transcript pairs is in 
general positively correlated and directed by bidirectional promoters in cases of 
overlapping divergent genes. By comparing with known sense-antisense pairs, 
our results raise the possibility that antisense transcripts could be regulating the 
expression of well-known tumor suppressors and oncogenes. This study 
provides a resource, oncoNATdb, a catalogue of cancer related genes with 
significant antisense transcription, which will allow cancer researchers to 
investigate the mechanisms of sense-antisense regulation and further advance 
our understanding of their role in cancer. 
These studies are presented consecutively in chapters 2, 3, and 4, 























Chapter 2  
Reconstructing targetable pathways in KRAS 
dependent lung cancers 
 






Activating mutations in the Ras oncogenes characterize 20-40% of all 
non-small cell lung cancer (NSCLC)9,97,98, the leading cause of cancer mortality 
in the United States99, which establishes Ras genes as the most commonly 
mutated oncogenes in this malignancy. KRAS, NRAS, and HRAS, the main 
members of this family of GTPase proteins, are activated by somatic mutations in 
20-30%, 1-5%, and 1% of the NSCLC cases respectively9. Mutated Ras has 
been implicated in activating numerous pathways that control cell proliferation 
and survival; however, development of drug therapies aimed at disrupting Ras 
activity has proved challenging9. Consequently, recent efforts have focused on 
identifying indirect mechanisms to disrupt Ras signaling by targeting either 
upstream activators or downstream effectors13,14,22,100,101. To this end, microarray 
gene expression profiling has been extensively used to define expression 
signatures characterizing Ras mutations in cell lines and tumors12,79,82, but gene 
signatures vary considerably across these studies. 
 
Complicating these initial studies, recent work has shown that NSCLCs 
with activating KRAS mutations can be stratified into KRAS-dependent (KRAS-





mutant KRAS signaling to sustain growth and proliferation10,13,101,102.  Therefore, 
after shRNA knock down of KRAS, KRAS-Ind cells would grow at rates 
resembling cells treated with control shRNAs, while KRAS-Dep grow at slower 
rates. Here, gene expression profiles of NSCLC cell lines found that KRAS 
dependency correlated with a differentiated phenotype, whereas KRAS 
independency was associated with the epithelial mesenchymal transformation 
phenotype10,102.  Moreover, recent work associated KRAS dependency with 
activation of the Wnt signaling pathway in colorectal cancers102. Taken together, 
these results suggest that specific pathways are activated in KRAS-Dep cell lines 
but not in KRAS-Ind cells, and that those pathways play a role in the varying 
disease phenotypes found in these cancers. 
 
While such expression profiling studies are useful for the analysis of 
KRAS signaling, it is well established that KRAS frequently exerts oncogenic 
functions through changes in protein abundance or post-translational 
modifications of proteins, specifically kinases that in turn induce a signaling 
cascade of downstream effectors15,17,40,103. Consequently, global transcriptome, 
proteome and phosphophospho-proteome profiling methods should be applied in 
order to identify causative pathways in KRAS-Dep and KRAS-Ind NSCLC cells in 
an unbiased fashion.  However, to date no study has comprehensively integrated 
these diverse sets of data14,15,18,40,79,82,103, leading to potential biases and 
inadequacies in our understanding of the mechanistic basis for KRAS function in 
NSCLC. 
 
One reason why such studies are lacking is because integration of such 
diverse datasets is a major challenge with existing integrative methods.  Yet 
when employed, integrative methods have been successful in building more 






2.2 Aims of this study 
 
In this study we generate a matched dataset of KRAS-mutated NSCLC 
cell lines with global and unbiased transcriptome, proteome and 
phosphoproteome profiles.  We develop a bioinformatics approach to integrate 
these disparate omics datasets and nominate biologically informative signaling 
modules using network analysis.  We find that KRAS-dependent cell lines harbor 
an active and targetable sub-network composed of lymphocyte-specific tyrosine 
kinase (LCK), cMET, KRAS and the p21 serine/threonine activated kinase 
(PAK1).  We characterize a KRAS-LCK-PAK1 pathway and show that KRAS-
Dep, but not KRAS-Ind cell lines require LCK for proliferation. This KRAS-LCK-
PAK1 network further coordinates anti-apoptotic pathways both through inhibition 
of pro-apoptotic proteins such as BAD and/or activation of anti-apoptotic proteins 
in KRAS-Dep cell lines.  In summary this study identifies active networks 
associated with the KRAS-dependent phenotype in NSCLC and nominates a 
novel KRAS-LCK-PAK1 pathway in KRAS-Dep cells that may serve as a 
druggable pathway for treating KRAS-dependent lung cancers. 
 
2.3 Bioinformatics Methods 
2.3.1 Protein quantification by label free LC-MS/MS 
 
The mass spectrometry proteomics and phosphoproteomics data have 
been deposited to the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org) via the PRIDE partner repository 
with the dataset identifier PXD000439. The general workflow used for label-free 
phosphoproteome quantification is summarized in the following steps26-41: 
sample preparation, phospho-peptides enrichment, label-free quantitative 
tandem mass spectrometry, peptide identification through database search, and 
quantification by the spectral count method. Cell lines were grown on vendors 





and sample preparation was performed as previously reported40 in the presence 
of proteases and phosphatases inhibitors.  
 
For mass Spectrometry eluted proteins were separated by 1D SDS-PAGE 
(4-12% Bis-Tris Novex-Invitrogen, Carlsbad, CA).  24 equal-sized gel bands were 
excised and subjected to in-gel tryptic digestion.  Because phospho-peptides 
correspond to a small fraction of all peptides of after tryptic digestion, phospho-
peptide enrichment was performed using immobilized metal affinity 
chromatography (IMAC). Tryptic peptides were then divided into two fractions: 
phospho-enriched and flow-through or unmodified peptides. Both fractions of 
extracted peptides were independently reconstituted with mobile phase A prior to 
on-line reverse phase nanoLC-MS/MS (LTQ-Velos with Proxeon nanoHPLC, 
ThermoFinnigan).   Peptides were eluted on-line to the mass spectrometer with a 
reverse phase linear gradient from 97% A (0.1 % formic acid in water) to 45 % B 
(0.1 % formic acid in acetonitrile) over 60-minutes.   Peptides were detected and 
fragmented in the mass spectrometer in a data-dependent manner sending the 
top 12 precursor ions that exceeded a threshold of 500 ion counts, excluding 
singly charged ions, for collisional-induced dissociation.  Dynamic mass 
exclusion was enabled with a repeat count of 2 for 1.5 minutes for a list size of 
500 m/z.  
 
For the database search raw spectra files were converted to mzXML using 
ReadAW.  The mzXML files were searched using X!Tandem with the k-score 
plug-in104. The proteomic searches were performed using the following options: 
allow up to 2 missed tryptic cleavages, a parent ion tolerance window of -1 to +4 
Daltons, and a fragment ion tolerance of 0.8 Da. The following variable 
modifications were allowed: phosphorylation of Serine, Threonine, and Tyrosine 
(+79.966331@[STY]), oxidation of Methionine (+15.994920@M), and 
carbamidomethylation of Cysteine (+57.021460@C). All protein searches were 
performed using the Human Refseq protein database (release 47). Appended to 





sequences to serve as decoys105,106. The X!Tandem results were then post 
processed with PeptideProphet and ProteinProphet58,59. Spectral counts were 
then obtained for all of the proteins identified in our cohort of 13 cell lines using 
the Abacus software tool107. For Abacus, the following parameters were used:  
count only peptide-to-spectrum-matches (PSMs) with a PeptideProphet score 
above 0.5 (iniProbTH=0.50), retain only proteins with at least one peptide with a 
PeptideProphet score above 0.99 (maxIniProbTH=0.99) and a ProteinProphet 
probability greater than 0.9 in the COMBINED file (minCombinedFilePw=0.90).  
For the phosphorylated fraction, peptides were required to have at least one 
phosphorylated Serine, Threonine or Tyrosine 
(reqAAmods=+S[167];+T[181];+Y[243]). Proteins and phospho-proteins identified 
with at least one spectral count in two independent cell lines were kept for 
downstream analysis (Balbin et al., 201370, Supplementary Data 1, 3), while 
those identified in one cell line only were filter out (Balbin et al., 201370 
Supplementary Data 2, 4).  
 
The spectrum counts for each protein were normalized with respect to the 
total number of spectrum counts within each sample. This normalization was 
applied independently for unmodified and modified proteins. Common 
contaminants and “Deja vu”108 proteins were filter out before quantification of 
differentially abundant proteins.  For both, unmodified and phosphorylated 
proteins, the fold change was calculated with respect to the comparison KRAS-
Dep vs. KRAS-Ind cell lines. This fold change was then log transformed and z-
score normalized. Finally, the p-value was calculated using the standard normal 
distribution. The final master tables with the normalized spectrum counts for 
phosphorylated and flow through fraction for each cell line are provided as 
Supplementary Data 1 and 2 in Balbin et al 2013.  
 
Phospho-enrichment was calculated as the ratio between the number of 
phospho-peptides identified and the total number of peptides (phosphorylated 





match (bestInitProbability). All enrichment calculations were made using only 
peptides that have Ser, Thr or Tyr in them. Peptides without any of those amino 
acids were excluded from the calculation. Finally, the phospho-enrichment value 
is taken for a PeptideProphet score above 0.94 (bestInitProbability=0.9413), 
which produces a 0.01 FDR. The calculated phospho-peptide enrichment, for all 
samples, ranges from 26 to 38%.  
 
2.3.2 Gene Expression Data 
 
Gene expression data used in this study are publicly available at 
ArrayExpress with accession number E-MTAB-783. Gene expression was scaled 
and log2 normalized previous to additional downstream analysis. 
 
2.3.3 Integration of Datasets 
 
Because different protein functional groups (e.g. transcription factors, 
kinases or secretory proteins) have distinct gene expression dynamic range, the 
gene expression dataset was split into two different categories: “informative” 
genes and “all other” genes and subsequently analysis were performed 
independently on each one of them. “Informative” refer to genes that are well 
known to drive a carcinogenic process such as KRAS, TP53, ERBB2 and 
CDKN2A, etc., as well as to genes that could have the potential to drive 
oncogenesis as kinases, phosphatases among others. A list of “Informative” 
genes was compiled by combining the Sanger’s cancer census genes, all 
kinases and phosphatases as well as additional and recently reported genes 
important for carcinogenesis (Balbin et al., 201370 Supplementary Data 8).  
 
Raw data was preprocessed as described in the experimental methods 
section. Phosphoproteome, proteome and transcriptome datasets were log 





comparison KRAS-Dep vs KRAS-Ind cell lines. The LFC was z-score normalized 
and a p-value was calculated using the standard normal distribution. 
 
In order to synthesize for each protein the information obtained from gene 
expression, protein and phospho-protein abundance, we calculated a combined 
abundance S score as 
∑ 	
∑
, where z is the z-transformed LFC of protein i 
in the dataset k, while w corresponds to the weight of each dataset 1⁄ . 
	represents the size of dataset k. 
 
Finally a p-value for the combined score was calculated using the 
standard normal distribution and then adjusted using the Hochberg procedure in 
order to correct for multiple hypothesis testing. 
 
2.3.4 Network Analysis 
 
We use the Signaling Pathway Impact Analysis Algorithm (SPIA109) in 
order to perform network enrichment analysis. The source code for this algorithm 
is available as an R package from http://bioconductor.org/biocLite.R. SPIA 
calculates the significance of a pathway according to both the over-
representation evidence (e.g. any commonly used enrichment test) and 
perturbation’s based evidence using the topology of the network. The KEGG 
database (http://www.genome.jp/kegg/kegg1.html) was used as the main source 
for pathway’s definition and we used the set of differential expressed genes as 
defined by the combined abundance score with adjusted p-value <=0.05 as the 
seed genelist. Significant pathways with FDR <=0.05 are reported (Table A-1). 
 
For the Network reconstruction methodology, we built a focused 
undirected and weighted protein-to-protein interaction network (G) using 





pathways were downloaded from the KEGG database and then merged into a 
unified meta-pathway (G) using the bioconductor KEGGgraph library . This 
meta-pathway (G) is provided for the interested reader as Supplementary Data 9 
in Balbin et al., 201370. 
 
We assigned weights to both nodes (V) and edges (E). Node weights 
correspond to the combined score (S) for differential abundance between KRAS-
Dep and KRAS-Ind phenotypes, while the edge weights correspond to the 
experimental confidence on that interaction as derived from the STRING 
database. For each edge in the meta-pathway, we obtained from STRING the 
experimental and physical interaction scores and then combined them into a 
single score using a naïve Bayes approach. In addition, in order to decrease 
redundancy, multiple gene family members with the same interaction partners 
were summarized into a “consensus gene” defined as the gene with highest 
scoring interaction neighborhood. This step is advised due to the node 
redundancy introduced within the KEGG database and the fact that the 
interactions for many gene family members are annotated by similarity to other 
members in the family and not by direct experimental validation. 
 
Finally, we used the Prize Collecting Steiner Tree (PCST) algorithm to find 
sub-networks, T, in the meta-pathway (G) that represent the most differentially 
abundant proteins connected through the most reliable interactions. Formally, the 
PCST is formulated as follows:  
		min ⊆ ;	 ⊆
, 	
∑ 	∈	 ∑ 	∈	 	[1] 
where 	 log 	 with  as the p-value for the S score of each 
protein, and 1 	∏ 	with  for the string score for the edge’s physical 
and experimental evidence. This choice of  and  assigns high values to the 
most differentially abundant proteins in the pathway, and low values to the high 
confidence interactions in the network. Finally, the constant  controls the trade 





of new edges and the prize gained by bringing in a new protein. 	 indirectly 
controls the size of the final sub-networks. All results presented here were 
obtained with =0.3. In order to choose	 , we solved the prize collecting steiner 
problem, varying  between 0.01-1 in increments of 0.01, and choose the value 
of  at which 60% of the essential nodes of simulated network of similar size 
were recovered. In order to solve the PCST, we used the implementation based 
on information message passaging described by 110, for which the source code 
availability is annotated in the Table A-2. 
 
The PCST has been used in similar settings before75,84,110 because it identifies 
sub-networks that represent cross talk between pathways, as well as “connecting 
proteins” that are not directly measured in the experiment but that are relevant to 




2.3.5 Analysis of LCK knock-down experiments 
 
We used the Signaling Pathway Impact Analysis Algorithm (SPIA) as 
described above to identify pathways specifically activated or inhibited after LCK 
knockdown (Table A-5), confirming the involvement of a lung cancer pathway but 
more importantly several pathways controlling apoptosis induction such as the 
natural killer cell-mediated cytotoxicity, Toll-like receptor signaling and the NOD-
like receptor signaling pathway. This is in agreement with the fact that Module 
M1 containing LCK and PAK1 were enriched for proteins belonging to the 
apoptosis pathways (Figure A.7A). Therefore, we focused the additional analysis 







To perform BCL2A1 nomination we first collect apoptosis gene concepts 
from KEGG, gene ontology and Reactome and generate a meta-apoptosis gene 
concept with all unique genes found. We reasoned that proteins specifically 
activated by LCK should simultaneously satisfy the following three 
characteristics: to be overexpressed when comparing KRAS-Dep vs KRAS-Ind 
cells, to be under-expressed when comparing the LCK knock down vs. the non-
targeting control in H441 and H358 cell lines and to be unaffected after knocking 
down any other gene in different cell lines. Characteristic 3 is included to control 
for changes in gene expression induced by any knockdown treatment 
irrespective of the gene of interest.  
 
Representing conditions 1, 2, and 3 in Cartesian plot results in a plot 
shown in Figure A.8A.  The x-axis shows the differential expression of those 
genes when comparing KRAS-Dep vs KRAS-Ind cell lines. The y-axis shows the 
average differential expression of the same genes when comparing a siRNA 
knockdown of LCK in H441 and H358 cell lines with respect to the targeting 
control (red dots), or the average differential expression when comparing the 
knockdown of a “random” gene compared to its respective control (black dots) in 
three unrelated prostate cell lines. Genes affected by the overall siRNA treatment 
would by overlapping or very close in this plot, while genes specifically affected 
by LCK would be located far apart in the y-axis. We measure this effect by taking 
the Euclidean distance between red and black dots representing the same gene 
in the above representation.  
 
Genes that are specifically affected by LCK would have positive or 
negative Euclidean distances according to the magnitude of their perturbation, 
while genes nonspecifically affected by the siRNA treatment would have 






2.4 Experimental Methods 
2.4.1 Cell lines 
 
All cell lines were obtained from ATCC and maintained using standard 
procedures.  Specifically, H441, H358, H2009, H1734, H727, H460, H2122, 
H1792, H23, H1155 cells were maintained in RPMI 1640 (Gibco) plus 10% FBS 
and 1% penicillin-streptomycin.  A549 cells were maintained in DMEM (Gibco) 
plus 10% FBS and 1% penicillin-streptomycin.  SKLU1 cells were maintained in 
DMEM/F12 plus 10% FBS and 1% penicillin-streptomycin. SW900 cells were 
maintained in L15 plus 10% FBS and 1% penicillin-streptomycin.  Cell lines were 
grown at 37°C in a 5% CO2 cell culture incubator.  All cell lines were genotyped 
for identity at the University of Michigan Sequencing Core. 
 
2.4.2 shRNA knock down studies 
 
For LCK and KRAS knockdowns all cells were plated at 100000 cells/ml in 
6 well plates and let them attached overnight. Cells were infected next day with 
the lentivirus RNA and 24 hours after infection old media was replaced with new 
cell media. Cells were allowed to grow for 96 hours in this fresh media. At this 
point cells were treated with 1mg/ml puromycin for 5 days to eliminate uninfected 
cells. Media was replaced and proliferation assays set up with the stable selected 
clones. Knockdown efficiency was confirmed by Western blot. shRNA sequences 
are provided in the supplementary methods. 
 
2.4.3 siRNA knockdown studies 
 
Cells were plated in 100mM plates at 30% confluency and transfected 
twice at 12 hours and 24 hours post-plating.  Knockdowns were performed using 





(Invitrogen) in Opti-MEM media (Gibco).  Knockdown efficiency was confirmed by 
Western blot.  siRNA used are listed in the supplementary methods. 72 hours 
post-transfection, cells were rinsed twice with 10mL PBS, harvested with a 
rubber policeman in 1mL PBS and centrifuged for 5 min at 2,500x g.  The 
supernatant was discarded and the cells were prepared for Western blot 
analysis. 
 
2.4.4 Western Blots 
 
Cell pellets were lysed in RIPA lysis buffer (Sigma) supplemented with 
HALT protease inhibitor and phosphatase inhibitor (Fisher).  Western blotting 
was performed using standard protocols.  Briefly, protein lysates were boiled in 
sample buffer for 5 min at 98C and 10ug of protein was separated by SDS-PAGE 
gel electrophoresis.  Proteins were transferred onto a PVDF membrane (GE 
Healthcare) and blocked for 30 minutes in blocking buffer (5% milk in 1x TBS 
supplemented with 0.1% Tween (TBS-T)).  Membranes were incubated with 
primary antibody overnight at 4C and then with secondary antibody for 2 hours at 
room temperature.  Signals were visualized by enhanced chemiluminescence 
system (GE Healthcare). The primary antibodies used are listed in the 
supplementary methods and full blots can be found in Supplementary Fig S9-S15 
in Balbin et al., 2013. 
2.4.5 Proliferation Assays 
 
Proliferation assays were performed with stable clones of the scramble 
RNA, and two independent constructs against LCK or KRAS for each cell line. 
Cells were plated at 30000 cells/ml in 24 well plates and cell counts were taken 
with a Beckman coulter Z2 particle count instrument every 48 hours for 8 days. 





2.4.6 WST Drug Assays 
 
Cells were plated in a 96-well plate 12 hours prior to drug treatment at a 
density of 3500 cells per well in a 100ul of growth media.  Desired concentrations 
of LCK Inhibitor (Santa Cruz, sc-204052,CAS 213743-31-8) and LCK Inhibitor II 
(Millipore, Lck Inhibitor II,CAS 918870-43-6) were prepared using growth media and 
100ul of the drug solution was added directly to the wells.  After 72 hours of 
incubation at 37C, 20ul of WST Cell proliferation reagent (Roche) was added to 
each well.  Following 2 hours of incubation at 37C, the absorbance of the wells 
was measured at 450nm. 
 
2.4.7 Confocal microscopy 
 
H460 and H441 cells were fixed with 3.7% paraformaldehyde, and then 
permeabilized with 0.1% (w/v) saponin for 15 min. Cells were co-incubated with 
primary antibodies against phosphor -catenin and total beta catenin for 12hr at 
4 °C, followed by incubating with appropriate Alexa-Fluor-conjugated secondary 
antibodies for 30 min at 37 °C. Cells were washed and mounted onto glass slides 
using Vectashield mounting medium containing DAPI. Samples were analyzed 
using a Nikon A1 laser-scanning confocal microscope equipped with a Plan-Apo 
×63/1.4 numerical aperture oil lens objective. Acquired images were then 
analyzed using ImageJ software (version 1.41o). 
 
2.4.8 KRAS Genotyping 
 
Genomic DNA from resected lung cancer tissue samples was prepared 
using a Qiagen Blood and Tissue Kit (Qiagen) according to the manufacturer’s 
instructions.  KRAS mutations were determined using standard RT-PCR and 
Sanger sequencing protocols for KRAS exon 1, which harbors codons 12 and 13, 





DNA with 38 cycles of PCR according to the following conditions: 94C for 30 
seconds, 56C for 30 seconds, 68C for 45 seconds.  PCR products were 
subsequently purified using ExoSAP-IT PCR purification product 
(USB/Affymetrix) according to the manufacturer’s instructions.  PCR products 
were then unidirectionally sequenced using the M13 forward primer at the 
University of Michigan Sequencing Core.  Sequence data was analyzed for the 
presence of canonical activating KRAS mutations at codons 12, 13, and 61. 




Immunohistochemical (IHC) analyses on paraffin-embedded formalin-fixed 
(FFPE) tumor tissue sections were carried out using the automated DiscoveryXT 
staining platform from Ventana Medical Systems. All FFPE sections were 
represented in triplicate on the tissue microarray.  The primary rabbit monoclonal 
LCK antibody was obtained from Cell Signaling (#2984).  Antigen recovery was 
conducted using heat retrieval and CC1 standard, a high pH Tris/borate/EDTA 
buffer (VMSI, catalogue no. 950-124). Slides were incubated with 1:50 of the 
LCK antibody (Cell Signaling) overnight at room temperature.  Primary antibody 
was detected using the ChromoMap DAB detection kit (VMSI, catalogue no. 760-
159) and UltraMap anti-Rb HRP (VMSI, catalo no. 760-4315).  The anti-Rb HRP 
secondary antibody was applied for 30 minutes at room temperature.  Slides 
were counterstained with Hematoxylin for 10 minutes followed by Bluing Reagent 
for 5 minutes at 37C.  Staining was scored (DG Beer) as negative (score = 0), 
minimal (score = 1), weak (score = 2), moderate (score = 3), or high (score = 4). 
 
2.5 Results 






To study KRAS function in lung cancer, we generated matched global 
transcriptome, proteome and phosphoproteome datasets for a panel of KRAS-
Dep and KRAS-Ind NSCLC cell lines, as well as a bioinformatics methodology to 
integrate all those data types (Figure 2.1A). Transcript, protein and phospho-
protein abundance were measured by microarrays and label free LC-MS/MS 
respectively (Methods). We identified 3213 proteins in the unmodified state and 
1044 proteins in the phosphorylated state, with at least 1 spectrum count in two 
independent cell lines. The number of unique peptides and phospho-peptides for 
each cell line are shown in the Figure A.1A, Figure A.1B, and the full proteome 
and phosphoproteome datasets for all cell lines are given in Balbin et al 201370 
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A) A panel of KRAS-dependent and -independent cell lines was interrogated by transcriptomics, proteomics 
and phospho-proteomics techniques. Transcripts were split in two different categories: “informative” genes 
and “all other” genes. Proteome and phopho-proteome datasets were normalized with respect to the total 
number spectral counts in each library, and common contaminants and “Deja vu” proteins were filtered out 
before quantification of differentially abundance. All datasets were log transformed and the log fold change 
(LFC) was taken with respect to the comparison KRAS-Dep vs KRAS-Ind cell lines. The LFC was z-score 
normalized and a p-value was calculated using the standard normal distribution. The combined S score was 
used to integrate all three datasets (methods) and select differentially expressed proteins. Network and 
enrichment analysis were performed using the Signaling Pathway Analysis Algorithm (SPIA) and the Prize 
Collecting Steiner Tree Algorithm (PCST). B) Naïve integration of datasets. Only ~ 5.2 % of the proteins are 
shared among two of the datasets (adjusted p-value <= 0.05 was used as a threshold to select differentially 
expressed proteins). A major drawback of this method is the absence of an objective criterion to include 
proteins differentially expressed in only one dataset. C) A meta-integration of the independent signatures 
using the combined S score (S). The S score integration improves by five-fold the percentage of shared 
proteins among datasets (~ 26 %), and defines an objective rule for including proteins differentially 
expressed in one, two or all datasets. D) Integrative analysis of transcriptome, proteome and phospho-
proteome nominates receptor tyrosine kinases MET and ERBB3, Src family members LCK and LYN, PAK1, 
and CTNNB1, CTNNA1, and CDH1 among others as differentially “activated” proteins in KRAS-Dep cell 
lines. Left) Presence/absence heatmap. Proteins that are differentially abundant in a particular dataset are 
represented in yellow and unaffected proteins are represented in blue. Middle) Combined S score (S) for all 
differentially abundant proteins in KRAS-Dep vs KRAS-Ind cell lines. Right) Combined statistical significance 
each differentially abundant protein. –log of the Hochberg adjusted p-value, -log(0.05)= 1.30. 
 
 
Integration of transcriptome, proteome and phosphoproteome data is 
challenging due to differences in technological methods and detection power. 
Hence, we first calculated the log fold change (LFC) in transcript, protein and 
phospho-protein abundance between KRAS-Dep and KRAS-Ind cell lines. We 
then correlated LFC mRNA abundance with LFC protein abundance as well as 
LFC protein abundance with LFC phospho-protein abundance. We found 
generally low to intermediate correlations, which is consistent with previous 
studies describing intermediate correlations between mRNA and protein 
abundance 111-113 (Figure A.2A, B) Correlation between LFC transcript and LFC 
protein 95 confidence interval (CI) = 0.29 - 0.36, p-value <= 2 x 10-16; correlation 
between LFC unmodified protein and LFC phospho-protein 95 CI=0.29 - 0.43, p-
value <=2 x 10-16).  
 
A naïve method of integrating those diverse sets of data is either to look 
for genes that are differentially abundant at the transcript, protein and phospho-
protein level or to look for genes differentially abundant in at least one of these 





transcripts, 173 differentially abundant proteins in the unmodified state and 61 
differentially abundant proteins in the phosphorylated state (Figure 2.1B and 
Supplementary Data 5 provided in Balbin et al., 2013). However, naïve 
integration commonly produces a limited number of proteins that are differentially 
abundant across all signatures. Out of the 862 unique proteins called as 
differentially abundant, only 2 proteins are shared across all signatures and 45 by 
two independent datasets (Hochberg-adjusted p-value <=0.05, Figure 2.1B) 
resulting in only a ~ 5.2 % overlap among signatures. Furthermore, naïve 
integration typically produces a final list of differentially abundant proteins that is 
dominated by proteins identified only in the largest dataset, the transcriptome in 
this case (Figure A.2C). Moreover, this list is enriched in genes that appear not to 
be causative cancer genes but which have a high dynamic range of expression 
(Figure A.2D, A2E, A2F). 
 
In order to address these issues, we developed a bioinformatics 
methodology to integrate transcriptomics, proteomics and phosphoproteomics 
datasets that aims at identifying differentially abundant proteins that are 
nominated as such by any combination of these datasets. This methodology 
focuses on identifying proteins that change consistently across transcript, protein 
and phospho-protein levels as they constitute candidates that can be uniformly 
assessed, and therefore potentially used for interrogating tissue samples at 
either the protein, phospho-protein or transcript level with similar results.  
 
We first distinguish between “informative” and “all other” genes and assign 
weights to each dataset in proportion to that dataset’s size (Figure 2.1A, and 
Methods) in order to control for differences in the dynamic range of different 
proteins and the coverage of each “omics” dataset. We then calculate the 
combined “abundance score”, S, to measure the overall differential abundance of 
a protein across all datasets as 
∑ 	
∑
, where z is the z-transformed LFC of 





1⁄ . 	represents the size of dataset k. Our score is inspired by the 
Stouffer’s score that is used for meta-analysis114. Variations of the Stouffer score 
have been previously used to aggregate multiple studies involving only one type 
of “omics” datasets, such as microarrays115.  
 
Moreover, although other integration methods such as the combined 
Fisher p-value or the scores proposed by Ramasay et al., and Huang et al.,75,115 
could be used for nominating differentially abundant proteins, when compared to 
those methods the S score demonstrates several key advantages for 
discriminating informative genes. First, because the S score normalizes the 
original data into z-scores, the combined distribution is also normal, allowing for 
simple statistics (Figure A.3A). Second, the weight for each dataset is flexibly 
defined, i.e. according to the size of the dataset. Third, the S score can identify 
consistently changing proteins that would be missed otherwise (Figure A.3B). 
Fourth, because the S score is based on the average of  and the fisher method 
on the average of -log(p-value), these scores follow a close linear relationship for 
most values of S. Deviations of this linear relationship are observed for extreme 
values of S and instances where the transcript, protein and phospho-protein 
abundances change in discordant directions  (Figure A.3C). Therefore, the 
combined used of the Fisher and S scores could identify proteins with discordant 
changes in abundance. In summary, by using the S score we defined a metric for 
selecting transcripts, proteins and phospho-proteins that are differentially 
abundant uniquely or consistently across different datasets, overcoming the 
drawbacks of naïve integration. 
 
Our S-score analysis of the phosphoproteome, proteome and 
transcriptome nominated 115 differentially abundant proteins at a Hochberg-
adjusted p-value <= 0.05. Out of the 115 proteins, 30 were nominated uniquely 
by our method and were missed using naïve integration of the datasets (Figure 





state, 28 proteins in un-phosphorylated state and 6 transcripts that were 
differentially expressed would have been unattended by a naïve approach 
(Figure 2.1C). By using the S score, the percentage of overlap among datasets in 
the list of differentially expressed proteins is ~26 %, which represents an 
increase of five-fold with respect to the naïve integration approach. Moreover, 
genes identified by our method show higher correlation between the LFC 
abundance of the transcript and protein in unmodified state as well as the protein 
in unmodified and phosphorylated state (Figure A.2A, Figure A.2B). We also note 
that the list of differentially expressed genes nominated by the S score is 
enriched for proteins with functions such as kinase, phospho-transferase activity 
and alternative splicing, and localized both in the cytoplasm and nucleus (Figure 
A.2G). These functions are expected for proteins in signaling cascades, such as 
the ones downstream of KRAS, but these functions were completely missed on 
the proteins nominated by the naïve integration approach. 
  
Finally, comparison of NSCLC KRAS-Dep cell lines against KRAS-Ind cell 
lines showed that of 115 proteins nominated by our integrative analysis, 68 also 
demonstrated increased mRNA, unmodified protein or phosphorylated protein 
abundance in KRAS-Dep cells, whereas 47 were found to be decreased (Figure 
2.1D, Supplementary Data 6 provided in Balbin et al., 2013). Of the 68 that were 
increased, 57 proteins are classified as phospho-proteins, 14 as kinases, 8 as 
proto-oncogenes and 9 as involved in lymphocyte activation among other 
functions. Similarly, out of the 47 genes that were decreased, 37 are classified as 
phospho-proteins, 8 as kinases and 5 as proto-oncogenes among other 
functions. These results demonstrate that our analysis is able to identify 
functionally relevant proteins by integrating the transcriptome, proteome and 







2.5.2 Validation in NSCLC cell lines 
 
To confirm our computational predictions, we employed a panel of 13 
NSCLC cell lines for experimental studies, for which profiles of somatic mutations 
is provided in Table A-3.  Of these, 8 have been defined as KRAS-Ind and 5 
have been defined as KRAS-Dep based on previous studies 10,102 and confirmed 
in our hands.  We selected highly ranking proteins predicted to be up-regulated in 
KRAS-Dep but not KRAS-Ind cells for further experimental validation.  Of the top 
20 nominated proteins, we included several proteins known to be associated with 
KRAS dependency in colorectal cancers (CTNNB1, PAK1) 102,116 and others that 
have not been implicated to date (LCK and cMET) with the KRAS-dependent 
phenotype in any cancer (Figure 2.2). Western blot analyses of these proteins 
and their phosphorylated forms validated that cMET, LCK, PAK1, and -catenin 
were enriched in expression in KRAS-Dep cell lines.  Furthermore, 
phosphorylated forms of these proteins were also specific, suggesting that these 
proteins are activated in KRAS-Dep cells.  These experiments validate our 
computational method and suggest that the S score accurately identifies proteins 
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2.5.3 Network analysis identifies active modules in KRAS-Dep cells 
 
We next developed a three-step methodology for reconstruction of 
biological modules associated with KRAS status (Figure 2.3A). In the first step, 
we identified differential expressed pathways using the Signaling Pathway Impact 
Analysis algorithm (SPIA 109). We then build a focused undirected and weighted 
protein-to-protein interaction network (G). Finally, in the third step, we used the 
Prize Collecting Steiner Tree algorithm to find sub-networks, T, in the weighted 
protein-protein interaction network (G) that maximized the number of differential 
expressed proteins recovered as well as the confidence in their interaction 
(Methods). 
 
Specifically, in the first step we performed pathway enrichment analysis 
using SPIA in order to identify pathways with overall increased or decreased 
activity in KRAS-Dep cell lines (Figure A.4A). SPIA calculates the significance of 
a pathway according to both a gene set over-representation index and a 
network’s perturbation index that takes into consideration the topology of and 
interactions within the pathway (Methods). This analysis revealed activation of 
main signaling programs in KRAS-Dep NSCLC cell lines when compared to 
KRAS-Ind, such as the ERBB signaling pathway, cancer specific associated 
pathways and tight junctions/cell adhesion pathways (Figure A.4B). Interestingly, 
immune-related signaling modules such as the T cell receptor, natural killer cell 
mediated cytotoxicity and Fc epsilon RI pathways were present, which suggested 
a relationship to LCK as immune-predominant kinase aberrantly up-regulated in 
KRAS-Dep cells. Moreover, although cancer associated-pathways are expected 
to appear enriched in our analysis of cancer cell lines, it is remarkable that the 
cancer pathways enriched in KRAS-Dep cell lines correspond to cancers types 
driven by activating Ras oncogene mutations (Figure A.4C), suggesting that 
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differential abundance between KRAS-Dep and KRAS-Ind phenotypes, while the edge's (Ce) weight 
correspond to the experimental confidence of that interaction as reported for the STRING database. Finally, 
we used the Prize Collecting Steiner Tree algorithm to find sub-networks, T, in G that maximized the number 
of differential expressed proteins recovered as well as the confidence in their interaction. B) Module M1. 
This module, identified by the PCST, connects LCK and PAK1 in KRAS-dependent cell lines. The module 
joins LCK and PAK1 with other proteins that belong to the NF-Kappa  and apoptosis pathways such as 
NFKBIA, NFKBs, TRAFs, and BIRCs. Node size is proportional to the absolute value of the combined S 
score. Node color represents over-expressed (red) or under-expressed (green) in KRAS-Dep cells. Edge 
thickness corresponds to edge’s confidence as calculated from STRING database (methods). C) Module 
M2. This module, identified by the PCST, involves KRAS and MET in KRAS-dependent cell lines. Additional 
targetable proteins such as SYK and LYN are also part in this module. Described as in b. D) Module M3. 
This module, identified by the PCST, connects CTNNB1 (-catenin), CTNNA1, CDH1, TJP2 and other 
proteins associated cell adhesion complexes and the tight junction pathways. Described as in b. 
 
 
Furthermore, in the second step we built a focused undirected and 
weighted protein-to-protein interaction network (G) using all proteins that belong 
to those pathways identified by SPIA and we assigned weights to both nodes (V) 
and edges (E). The weight of each Node (Bi) corresponds to the combined score 
(S) for differential abundance between KRAS-Dep and KRAS-Ind phenotypes, 
while the weight of each edge (Ce) corresponds to the experimental confidence 
on that interaction. The edge weight is derived from the STRING database 117, by 
combining STRING’s experimental and physical interaction scores using a naïve 
Bayesian approach. 
 
Finally in the third broad step of this methodology, in order to identify 
specific network sub-modules that are active in KRAS-Dep cell lines, we 
formulated this network reconstruction task as a Prize Collecting Steiner Tree 
(PCST) problem75,84,96,110 (Methods). The PCST allowed us to synthesize 
transcriptome, proteome and phosphoproteome signatures in the context of the 
weighted protein-to-protein interaction network mentioned above. This 
formulation facilitated the identification of crosstalk between pathways nominated 
by SPIA, as well as identification of relevant proteins that were not directly 
measured in our experiments. We identified three modules –referred to as M1, 






M1 contains LCK, PAK1, and PRKCH as well as proteins involved in 
regulation of inflammation, antiviral responses and apoptosis proteins such as 
several TRAFs, BIRCs and NFKBs (Figure 2.3B). M2 contains KRAS as well as 
the kinases MET, LYN, SYK, and MAPK1 among others (Figure 2.3C). M3 
contains CTNNB1 (-catenin), CDH1, CTNNA1 (-catenin), TJP2 and other 
proteins associated with the adhesion complex (Figure 2.3D). M3 is consistent 
with our observation that -catenin is mainly localized in the cellular membrane 
of KRAS-Dep cells (Figure A.4D), supporting a role in cellular adhesion in 
NSCLC cell lines.  
 
2.5.4 KRAS-LCK-PAK1 signaling axis in KRAS-Dep lung cancer 
 
Intriguingly, module M1 suggests a link between LCK and PAK1 that has 
not been reported previously in solid tumors despite the fact that PAK1 
overexpression has been already implicated in lung and breast cancers118. LCK 
is a tissue-specific kinase normally expressed in T-lymphocytes.  It is commonly 
overexpressed in myeloid and lymphocytic leukemia, as well as Burkitt and non-
Hodgkin’s B-cell lymphoma 119 and acts as a proto-oncogene, inducing cellular 
transformation through regulation of cell proliferation and survival119,120.  A role 
for LCK is not known in solid tumors.  Therefore, we hypothesized that the 
aberrant overexpression of LCK in KRAS-Dep lung cancers could also play a role 
in this disease. 
 
To confirm our network reconstruction approach and further dissect the 
functional connections among KRAS, MET and LCK, we performed knockdown 
experiments using independent siRNAs in the H441 and H358 cell lines that 
display KRAS dependency10.  Immunoblot analysis showed that knockdown of 
KRAS decreased the abundance of MET, phospho-MET, LCK, phospho-LCK, 
phospho-PAK1/2 and phospho-BAD (Figure 2.4A, Figure A.5A, A.5B).  These 



















ces total and 
lines. Knock do


















am of LKC in
 KRAS-Dep c









in levels of LC
ell lines. Knoc
ut not their pr
dent cell lines.
es LCK and M
phorylation lev
K and MET, b
kdown of LCK













does not affect phosphorylation or protein level of LCK in H441-Dep cell line. D) LCK knockdown increases 
the level of cleaved PARP and caspase-3, markers of apoptosis in H441 KRAS-Dep cell line. 
 
KRAS and regulated by KRAS in vitro.  In contrast, knockdown of LCK did not 
reduce KRAS levels indicating that LCK does not regulate KRAS protein 
abundance (Figure 2.4B, Figure A.5C), although previous reports have 
suggested a role for LCK in KRAS activation121.  Knockdown of LCK did however 
reduce phospho-PAK1/2 levels, but not total PAK1/2 protein, defining PAK1/2 as 
targets for LCK-mediated phosphorylation (Figure 2.4B, Figure A.5C). Figure 
2.3B indicates that this effect is potentially mediated through a small network of 
interacting proteins. Moreover, knockdown of PAK1/2 did not change the 
phosphorylation or protein levels of LCK, confirming that PAK1 and PAK2 are 
downstream of LCK (Figure 2.4C). Taken together, our bioinformatics and 
experimental results suggest an active KRAS-LCK-PAK1/2 network in KRAS-
Dep cell lines (Figure A.5D). Our results also present evidence that KRAS can 
influence both the phosphorylation and protein levels of LCK and MET kinases, 
which complements previous reports suggesting that those kinases could be 
upstream of the RAS-MEK pathways121,122, and suggests the possibility of a 
feedback loop among these proteins in KRAS-dependent cells (Figure A.5D). 
 
2.5.5 KRAS-Dep cells are also dependent on LCK for proliferation 
 
In order to extend our results and investigate potentially aberrant 
expression of LCK in other cell lines, we performed a gene outlier expression 
analysis on an extended panel of 122 lung cancer cell lines (11 KRAS-Dep, 18 
KRAS-Ind and 93 KRAS-WT) (Methods). We evaluated informative genes 
observed as outliers in KRAS-Dep but not in KRAS-Ind cell lines (Figure 2.5A).  
 
This analysis revealed LCK, MET, ERBB3, MST1R and LYN are kinases 
that frequently exhibit outlier expression in KRAS-Dep cell lines, with expression 
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confirms high levels of LCK in KRAS dependent cell lines and none or negligible expression in KRAS-Ind or 
WT cell lines.  Cell line H2347 (blue label) harbors NRAS Q61K mutation, but its dependency status could 
not be established. Bar height corresponds to the average over three independent replicates and error bars 
are defined as s.e.m. 
 
 
By contrast, the kinases DIRK4 and MARK4 showed outlier expression in KRAS-
Ind cell lines (Figure 2.5A).  To validate our approach, we experimentally 
confirmed that LCK is overexpressed in KRAS-Dep cells using quantitative PCR 
on a panel of 43 lung cell lines (Figure 2.5C). 
 
Given that LCK is a known lineage-specific proliferation factor in B-
lymphocytes, we hypothesized that KRAS-Dep NSCLC overexpressing LCK also 
require this kinase for cell growth and survival.  We performed shRNA 
knockdown experiments for LCK and determined whether ablation of LCK activity 
with independent shRNAs could selectively impair cell proliferation on KRAS-Dep 
cells (Methods).  Figure 2.6A shows that knockdown of LCK dramatically impairs 
cell proliferation in KRAS-Dep cells but not KRAS-Ind cells, validating our 
predictions (shRNA1 t-test p-value=0.0001822, shRNA3 t-test p-value = 4.14 exp 
-6).  We further confirmed that independent knockdown of KRAS also produced 
similar results (Figure A.6A).   
 
Moreover, as a kinase, LCK is also an attractive candidate for strategies of 
targeted therapy.  While specific LCK inhibitors are still in development, we 
tested whether prototype small molecule inhibitors of LCK would selectively 
affect the viability of NSCLC KRAS-Dep cells.  We treated a panel of 3 KRAS-
Dep cell lines and 2 KRAS-Ind cell lines with increasing doses of LCK inhibitor 
(CAS 213743-31-8) and measured cell viability at different drug concentrations.  
All three KRAS-Dep cell lines tested in this experiment were sensitive to LCK 
inhibition while the KRAS-Ind cell lines were insensitive to LCK inhibition, as 
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in KRAS-Ind cell lines. Points represent the average over four independent experiments and error bars are 
defined as s.e.m. 
 
 
These results demonstrate that KRAS-Dep lung cancer cell lines have aberrant 
overexpression and activity of LCK.  Similarly, we observed that MET shRNA 
knockdown as well as MET inhibition with small molecule inhibitors selectively 
impaired cell growth of KRAS-Dep cell lines (Figure A.6C, Figure A.6D), further 
supporting the biological relevance of our computational network reconstructions 
and predictions of targetable proteins in KRAS-Dep cells. 
 
To evaluate whether LCK expression can be used to stratify the KRAS 
dependency status of human lung cancers, we assessed LCK expression in a 
panel of 29 lung adenocarcinoma tissue samples with mutations in KRAS. To 
confirm the KRAS mutations, we genotyped canonical positions in codons 12, 13 
and 61, known to produce a constitutively active KRAS when mutated (Table 
A-4). As there is currently no clinical biomarker to identify the KRAS dependency 
status of NSCLCs, we sought to evaluate LCK expression in these samples as a 
potential biomarker for KRAS dependency.  Because LCK is normally highly 
expressed in lymphocytes, LCK mRNA expression from surgical samples is not 
an accurate method to assess LCK expression in epithelial-derived lung cancer 
cells, as the infiltrating lymphocytes in these samples would distort the analysis. 
Thus, a previous study that detected LCK in lung cancer tissues by gene 
expression microarrays is likely confounded by the lack of cell-type specificity 123.   
 
We therefore used immunohistochemistry (IHC) to determine the 
abundance of phosphorylated LCK in epithelial lung cancer cells in our 29 clinical 
samples.  We first validated our IHC assay using a panel of normal tissues and 
cell lines that demonstrated high levels of LCK expression in the spleen where 
lymphocytes are abundant, but not in other tissue types. Next, a TMA of KRAS-





expression, while a TMA of H460 and H23 KRAS-Ind cell lines did not showed 
any staining.  Finally, applying this method to our 29 lung tumor samples 
harboring KRAS mutation, we found that 58.6% (17/29) of tumors showed high 
levels of phosphorylated LCK staining, whereas 41.4% (12/29) tumors showed 
low levels of phosphorylated LCK (Supplementary Table S1). These results are 
consistent with in vitro data demonstrating that KRAS-mutant lung cancer tissues 
can be subdivided in two groups according to their levels of phosphorylated LCK, 
similar to NSCLC cell lines. Although, it is not possible currently to determine the 
dependency status of a tissue through direct experimentation, this subdivision of 
tumor samples is suggestive of the correlation described here between KRAS 
dependency and LCK activation in cell lines. However, a larger cohort of tissues 
with matched profiles of KRAS mutation, gene expression as well as 
immunohistochemistry of phosphorylated LCK would be required to further 
determine the prognostic value and the extent of this association between KRAS 
dependency and LCK activation in tissue specimens. A proof of principle analysis 
in this direction is shown in Figure A.6E. 
 
2.5.6 KRAS and LCK could regulate anti-apoptosis pathways 
 
To explore potential functional roles of the KRAS-LCK-PAK1/2 pathway, 
we evaluated our computational predictions of modules M1, M2, and M3 in lung 
cancer.  We were struck by the enrichment for apoptosis-related proteins in 
module M1 that included LCK and PAK1 (Figure A.7A), suggesting a potential 
connection between LCK and apoptosis.  Indeed knockdown of LCK in H441 
cells was correlated with increased levels of cleaved PARP and caspase-3, 
markers of apoptosis, which further supports the association between LCK and 
apoptosis (Figure 2.4D).  
 
To further explore this association, we used microarrays to profile gene 





Dep cell lines, and we evaluated the microarray data for pathways specifically 
inhibited or activated by LCK (Table A-5 and methods for specific details on this 
analysis of these microarray data). We assumed that pathways activated 
specifically by LCK in the context of KRAS dependency would be inhibited after 
knockdown of this kinase.  Interestingly, we observed a module comprised of 
TRAF1, BIRC3 and BCL2L1, three proteins that regulate apoptosis (Figure 
A.7B).  These proteins were part of a canonical KEGG pathway for lung small 
cell cancer, a pathway specifically inhibited after LCK knockdown (Table A-5).  
 
Moreover, we reasoned that causative genes should be both 
overexpressed in KRAS-Dep compared to KRAS-Ind cell lines and also down 
regulated upon LCK knockdown in H441 and H358 (Methods).  Performing this 
analysis yielded BCL2A1, a BCL2-related protein A1 (Figure A.8A, A.8B). 
BCL2A1 can bind to and inhibit or neutralize pro-apoptotic multi-domain proteins 
such as BAK and BAX as well as pro-apoptotic BH3-only proteins such as tBID, 
BIM, PUMA, BIK, HRK and NOXA but not BAD 124. Pro-apoptotic protein BAD is 
inhibited when phosphorylated 125,126.  Indeed, knockdown of KRAS in H441 
decreased phosphorylation levels of BAD (p112, p136) (Figure 2.5A), which is 
consistent with increased levels of cleaved PARP observed in the knockdown 
samples (Figure 2.4A) and supports a role for KRAS in preventing apoptosis via 
BAD.  The effect on BAD phosphorylation was observed downstream of KRAS 
but not downstream of LCK or PAK1/2. Knockdown of LCK or PAK1/2 did not 
decrease phosphorylation levels of BAD suggesting independent mechanisms. 
 
Taken together, these computational and experimental data suggest a 
potential regulatory network in KRAS-Dep cells that both “directly” inhibits 
apoptosis by inducing phosphorylation of BAD and “indirectly” by modulating the 








The advent of high-throughput technologies has greatly advanced the 
study of cancer biology.  However to date, most studies employ only an individual 
technology and studies that do include multiple profiling technologies frequently 
analyze them separately without integrating across modalities.  While these 
approaches are effective for identifying single events in cancer (i.e. a new point 
mutation or an overexpressed gene), they do not uncover integrated biological 
modules that coordinate higher-level biological processes (i.e. apoptosis, RNA 
splicing, etc).   
 
Here we developed a novel method to integrate disparate profiling 
modalities to explore novel functional networks differentiating KRAS-dependent 
from KRAS-independent NSCLCs.  We used transcriptome, proteome, and 
phosphoproteome profiling to comprehensively analyze gene expression at the 
RNA and/or protein level, as well as signaling proteins activated or inactivated by 
post-translational modification.  Using this approach on 13 KRAS-mutant NSCLC 
cell lines known to be KRAS-Dep or KRAS-Ind, our integrative analysis 
nominated 115 proteins that were differentially abundant between these two 
groups (Hochberg-adjusted p-value <= 0.05).  Specifically, our method identified 
a set of proteins with highly correlated changes between transcript and protein 
levels or unmodified protein and phosphorylated protein levels, and then 
enriched these results for specific functions associated with KRAS.  Of these, we 
validated four proteins (LCK, MET, PAK1 and -catenin) selected from the top 20 
nominated genes.  LCK, MET, and PAK1 have not previously been studied in the 
context of KRAS-dependent lung cancer. 
 
Of particular interest to this study was LCK, a lymphocyte-specific kinase 
well studied in B-lymphocyte development 119,120 but uncharacterized in solid 





that has not previously been described.  We find that KRAS regulates LCK 
protein and phospho-protein levels, and LCK in turn regulates PAK1/2 
phosphorylation but not total protein levels.  Previous studies have identified a 
role for PAK1/2 in the phosphorylation of -catenin in KRAS-mutated colorectal 
cancer 102,116; however, we did not observe -catenin as a direct target of the 
KRAS-LCK-PAK1/2 pathway in lung cancer.  Knockdown of KRAS and LCK did 
not impact -catenin phosphorylation or cellular localization.  Indeed -catenin 
localized to the cell membrane in our experiments (Figure A.4D), not the cell 
nucleus where -catenin is known to be active in the stimulation of the Wnt 
signaling pathway 102,116.  In addition, our work finds that -catenin associates 
with the M3 reconstructed network module that also contains cell surface 
adhesion proteins such as CDH1, CTNNA1 (-catenin), and TJP2.  Thus -
catenin in NSCLC cell lines may operate through cell adhesion pathways as 
opposed to a role in regulating transcription as reported in colorectal cancer 102. 
This further helps to explain earlier observations that associate KRAS-Dep lung 
cancer cell lines with differentiated phenotypes 10. 
 
To explore the function of LCK in lung cancer, we performed knockdown 
experiments and observed that depletion of LCK impaired cellular proliferation 
and phenocopied knockdown of KRAS in KRAS-Dep cell lines.  In addition, small 
molecule inhibition of LCK resulted in preferential decrease in cell viability in 
KRAS-Dep cells.  Using the Prize Collecting Steiner Tree formulation, we also 
found that LCK was associated with a reconstructed Module M1 containing 
several proteins involved in regulation of apoptosis in addition to PAK1.  Indeed, 
we observed that knockdown of LCK or KRAS induces an increase in cleaved 
PARP levels indicating an increase in apoptosis. KRAS-Dep cells may then 
modulate apoptosis through two complementary mechanisms. KRAS may 
regulate the apoptotic response by regulating phosphorylation of BAD, while LCK 
may regulate BCL2-related anti-apoptotic proteins. Previous studies in T cells 





as LCK inhibition through small molecule inhibitors as an effective mean to 
sensitize those cells to apoptosis 119. Finally, we evaluated LCK expression in 
KRAS-mutant NSCLC tumors.  We observed that almost 60% (17/29) of the 
KRAS-mutated tumors showed high staining levels of phosphorylated LCK by 
IHC, suggesting they are likely KRAS-dependent. As projects such as The 
Cancer Genome Atlas (TCGA) approach their goal of enrolling thousands of 
patients with matched -omics datasets such as exome/genome and RNA 
sequencing and reverse phase protein arrays (among others), as well as detailed 
clinical follow ups, we will be able to assess the prognostic value of the LCK-
KRAS-PAK1/2 pathway in the context of KRAS dependency. A proof of principle 
analysis in this direction is presented in Figure A.6E.  
  
Taken together, this study establishes a potentially actionable pathway in 
KRAS-Dep NSCLCs comprised of KRAS, LCK, and PAK1/2.  We find that KRAS 
induces LCK activation, leading to a signaling cascade specific to KRAS-Dep 
cells that promotes cell proliferation and could reinforce a positive feedback loop 
with KRAS activity (Figure A.5D).  Furthermore, our study develops a method to 
integrate multiple proteomic and transcriptomic datasets for the identification of 
biologically relevant modules in cancer.  We thus provide a framework for the 
complex analysis of multiple cancer datasets to make biologically-informed 





Science is a collective enterprise and it is much more fun when done with 
friends and good collaborators. The results presented in this chapter were made 
possible because of the great collaboration and support of a team of people in 
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I want to dedicate this research to my father, Jesus William. Jesus William fought 
a very aggressive KRAS mutated colorectal cancer. While he was giving the fight 
for his life, I was, paradoxically, trying to find alternative ways to treat KRAS 
dependent cancers. Although, the results of this research were not on time to 












Chapter 3  
Identifying driver fusions in lung cancers 




3.1.1 Lung cancer 
 
Lung cancer is the leading cause of cancer-related deaths worldwide, 
generating more than a million deaths each year127,128. Lung cancer is 
histologically classified as either non–small cell lung cancer (NSCLC) or small 
cell lung cancer (SCLC). NSCLC accounts for 80% of all lung cancers and 
includes lung adenocarcinoma (LUAD), squamous cell carcinoma (LUSC) and 
large cell carcinoma (LULC).  Adenocarcinoma is the most prevalent subtype and 
most often observed in non-smokers, however tobacco smoking is associated 
with the majority of lung cancers129. The overall 5-year survival rate for lung 
cancer remains poor ~15%, due primarily to late diagnosis when tumor removal 
is no longer an option128. 
 
Genomic analyses of LUAD have revealed mutations in several well-
characterized tumor suppressor and oncogenes including TP53, STK11, KRAS, 
EGFR and BRAF among others2. These tumors also demonstrate copy number 
alterations with most occurring at relatively low frequency with some having 
therapeutic implications such as ERBB2 amplification130. Remarkably mutations 





TCGA for lung squamous cell carcinomas indicate that these tumors undergo 
TP53, FGFR1, DDR2, AKT1, PIK3CA, CDKN2A, MLL2, NOTCH1, and RB1 gene 
mutations as well as several recurrent gene copy number alterations in genes 
such as FGFR1, SOX2 and TP633. The heterogeneity observed in lung cancer 
both histologically and molecularly, underlie the difficulties in effectively treating 
patients with this disease. 
 
Similar to these known “driver” somatic gene mutations, several important 
gene fusions, formed by the breakage and re-joining of two different genes, occur 
in lung cancer including the EML4-ALK gene fusions identified in approximately 
4% of adenocarcinomas4,8. This fusion protein links the N-terminal portion of 
echinoderm microtubule-associated protein-like 4 (EML4) with the intracellular 
signaling portion of the anaplastic lymphoma kinase (ALK) tyrosine kinase 
receptor. The EML4-ALK translocation is mutually exclusive with EGFR and 
KRAS mutations and tumors with EML4-ALK translocation have fewer TP53 
gene mutations5. EML4-ALK gene fusions occur in LUAD and in never- or light 
smokers. Additional gene fusion events have now been identified in LUAD 
including ALK 131, ROS16, as well as RET7,8 kinases. These chromosomal 
rearrangements have been strongly associated with a history of never or light 
smoking.  
 
Most importantly, patients with tumors containing EGFR mutations show 
at least initial responsiveness to drugs that target these alterations20 and the 
presence of the EML4-ALK gene fusion is an indicator of therapeutic 
responsiveness to ALK inhibitors4. Under this logic, lung tumors with KIF5B-ALK 
fusions also have the potential for sensitivity to ALK inhibitors and RET fusions 
may be treated using drugs that target this kinase132. These chromosomal 
rearrangements have been strongly associated with a history of never or light 
smoking.  Our group also identified the NFE2-R3HDM2 and FGFR3 gene fusions 






3.1.2 Gene fusion detection and control of the false positive rate 
 
The increase on RNASeq experiments to study the cancer transcriptome 
has propelled the development of numerous algorithms for fusions discovery55-
57,135,136. A major task in fusion discovery is handling false positive. False 
positives can be generated during the sequencing and bioinformatics steps. In 
the sequencing step chimeric cDNA artifacts are generated by template switching 
during reverse transcription and amplification137. Template switching occurs 
when the nascent cDNA that is being synthesized dissociates from the template 
RNA and re-anneals to a different stretch of RNA with a similar sequence to the 
initial template, generating artifactual gene fusions137. This behavior is observed 
even more for highly abundant transcripts such as ribosomal RNA. In the 
bioinformatics step false positives are generated because all fusion discovery 
tools are error prone; they all identify fusion genes that are not present in control 
synthetic datasets138. Strikingly, the number of false positive fusions increased 
with read length for all tools, and all tools detected less fusion reads than were 
expected. 
 
A recent comparison of eight fusion calling algorithms showed that overall 
algorithms have a maximum sensitivity of about 80%. However, in order to 
recover the higher number of true positives, the most sensitive algorithms pay an 
extremely high prize increasing by several orders of magnitude the number of 
false positives. For example, TopHat-fusions (THF) and ChimeraScan the most 
sensitive algorithms produced well above 13000 false positive fusions in order to 
detect 27 true fusions139. False positives can be generated by the software or 
during the sequencing step. 
 
Taken together those results demonstrate that reducing the number of 
false positives would be the biggest challenge on a high throughput assessment 
of gene fusions across large cohort of patients, such as the TCGA cohorts and 






Previous studies have relied on applying hard thresholds to filter out 
potential false positives. For example establishing a minimum number of reads 
that support the gene fusion product. According to the identification of fusion 
boundary, the nucleotide coordinates defining the breakpoint of both genes 
involved in the fusion, we can define three types of reads: read spanning, read 
encompassing and mate pair encompassing reads (for pair-end sequencing). 
Encompassing reads harbor a fusion boundary and each read maps on a 
different gene of the fused gene couple; in spanning reads one mate overlaps 
with a fusion event, while the corresponding paired-end mate matches with one 
of the two genes involved in the chimera; lastly in mate pair encompassing reads 
one read maps to one side of the fusion boundary while its mate maps to the 
other side, but none of them harbor the fusion breakpoint.  
 
Although effective for blindly eliminating most false chimeric events, two 
issues appear with applying hard thresholds using the minimum number of reads. 
First, there are real and functional fusions such as EML4-ALK, which have a low 
read support despite being driver fusions. On the other hand, highly expressed, 
such as ribosomal proteins, tend to form a great variety of chimeric fusions due 
to template switching during the sequencing step. In consequence, thresholding 
approaches would eliminate real and functional fusions while keeping clear false 
positives.  
  
In this study, we address that challenge of controlling the false positive 
rate on fusion detection from a completely different perspective. Here, we 
developed a gene fusion classifier to distinguish between true and false 
positives. We used structural properties such as: 3’ and 5’ partner genes, cohort, 
3’ breaking exon, 5’ breaking exons, median alignment quality of reads that 
support 3’ gene, median alignment quality of reads that support 5’ gene, number 
of spanning reads, encompassing reads, spanning mate pairs, expression of the 





random forest algorithm for classification, because random forest algorithms do 
not make assumptions about the distribution of the data. Moreover, random 
forest algorithms determine the importance of each feature in the classification 
process and therefore they allow for feature selection. This approach showed to 
be very efficient while at the same time it recovered the main structural properties 
that are frequently used for thresholding.  
 
3.1.3 Aims of this study 
 
Given the importance of gene fusions, yet their apparent low frequency in 
lung cancer, in the present study we examine the landscape of gene fusions in 
the largest RNASeq cohort of NSCLC assembled so far. We have performed 
comprehensive RNA sequencing of our cohort of primary NSCLC with a history 
of heavy smoking and integrated the results with the available data from TCGA 
and another public available dataset, the “Seoul” cohort.  
 
We characterize gene fusions in lung tumors both with and without known 
driver mutated genes, and we examine the relationship between fusions 
incidence, tumor and clinical characteristics including patient survival. This is the 
first study to show that fusions incidence is an independent factor associated with 
poor prognosis. Moreover, we identified recurrent Neuregulin 1 (NRG1) gene 
fusion events exclusively in driver negative patients, resembling known kinase 
fusions, which may provide future therapeutic opportunities for patients harboring 
NRG1 rearrangements. This study also generates a database of lung cancer 







3.2 Bioinformatics methods 
3.2.1 Sequence alignment 
 
Sequence alignment was performed using the Tuxedo pipeline: Bowtie2 
(Bowtie2/2.0.2) and Tophat2 (TopHat/2.0.6)47. We supplied TopHat with the set 
of transcript models annotated in the Homo sapiens ensemble database version 
69. The flag fr-firststrand was used for the strand specific RNASeq libraries while 
fr-unstranded was used for the unstranded libraries. All other parameters were 
used with default values. 
 
3.2.2 Fusion calling 
 
Fusion calling was performed with TopHat-fusion47 (THF) on the UMICH, 
TCGA and Seoul cohorts. ChimeraScan56 was applied to the UMICH cohort to 
increase sensitivity in our discovery cohort. TopHat-fusion was run with the 
following arguments: bowtie, fusion-search, keep-fasta-order, no-coverage-
search, fusion-min-dist=0, fusion-anchor-length=13, fusion-ignore-
chromosomes=chrM. TopHat post-processing was run with the arguments: skip-
blast, num-fusion-reads=1, num-fusion-pairs=1, num-fusion-both=3. 
Chimerascan was run with the following options: trim5=1, trim3=1, 
frag_size_percentile=1.0, arg= -v, keep-tmp. 
 
3.2.3 Fusion annotation and lung cancers fusions database 
 
A database of fusions in lung cancers was developed, and for each fusion 
structural and functional annotation was recorded. The structural information 
correspond to chromosomes of 3’ and 5’ partner genes, cohort, 3’ chromosome, 
5’ chromosome, 3’ breaking exon, 5’ breaking exons, median alignment quality of 





gene, number of spanning reads, spanning mate pairs and encompassing reads, 
3’ and 5’ partner recurrence across the cohort and fusion type (Inter-
chromosomal, Intra-chromosomal, Tandem-duplication).  
 
The functional annotation corresponds to kinase status, oncogene status, 
tumor suppressor status and targetable status  (TRUE/FALSE) of both 3’ and 5’ 
partner genes. Other functional annotations include the gene family of both 
fusion genes, as well as the their gene biotype (protein-coding, ncRNA, rRNA, 
etc.). Moreover, the gene expression of each fusion gene was calculated in 
fragments per-kilobase per million (FPKM) using Cufflinks140 and stored in the 
database. In addition, an outlier score was calculated for the expression of both 
5’ and 3’ partners in order to identify cases in which the 3’ partner is highly 
expressed as consequence of the fusion event. 
 
This database was created using pytables and hd5 format for fast access 
and storage and includes the following tables: patient table, patient clinical 
information table, fusions structural information table and expression table. In 
addition to these tables corresponding to fusion events, we create an additional 
table to store the mutation status for each patient, mutation table. The mutation 
table allows us to classify each patient as “driver positive” or “driver negative” 
according to mutation status of well-known cancer related genes (see below). 
 
3.2.4 Fusions classifier 
 
As described in section 3.1.2 all fusion calling algorithms produce a 
significant number of false positive fusions when applied on RNASeq data. Many 
of these spurious fusions are due to diverse and difficult to model bioinformatics, 
sequencing and biological factors such as: template switching and random 





Therefore, in order to separate potentially genuine fusions from spurious 
ones, we developed a classifier to predict potentially true fusions based on the 
structural and functional features collected for each fusion, which were described 
above and stored in our fusion’s database. 
 
THF called 31,304 fusions across the combined cohort. The task of 
separating false positive fusions from potentially true ones in this dataset is then 
far from trivial. We first reason that functional fusion proteins have open reading 
frames (ORFs); therefore fusions in which the exon of one gene is fused to the 
intron of another or two introns are fused together would not produce fusion 
products with ORFs. This first level filtering reduced to 6,465 the number of 
fusions to classify. Then, we reason that fusions found in normal samples; 
fusions involving pseudogenes, lincRNAS, or antisense transcripts and fusions 
for which the median alignment quality of reads supporting any of the gene 
partners was equal to zero (indicating multi-mapping) are potentially false 
positives, and there were excluded from downstream analysis. This second level 
filtering reduced to 4,990 the number of fusions called by THF. Assessing the 
quality of each one of those fusions manually is impossible in practice.  
Therefore, we build a random forest classifier to determine the potentially true 
and false positives out those 4,990 gene fusions. 
 
For the classification step, we train a random forest classifier with 10,000 
trees using the following features: chromosomes of 3 and 5’ genes, 3’ gene, 5’ 
gene, 3’ breaking exon, 5’ breaking exons, median alignment quality of reads that 
support 3’ gene, median alignment quality of reads that support 5’ gene, number 
of spanning reads, spanning mate pairs and encompassing reads, 3’ and 5’ 
partner recurrence, fusion type, gene biotype of both 3’ and 5’ genes, FPKM 
expression of both 3’ and 5’ genes, and FPKM expression of both 3’ and 5’ 






True positives examples were selected from the TCGA, Seoul and UMICH 
cohorts. On one hand, the examples chosen from the TCGA and Seoul Cohorts 
correspond to well known fusions involving ALK, RET and ROS1 kinases. On the 
other, the examples chosen from the UMICH cohort correspond to fusions called 
by at least two independent algorithms, carefully curated manually and validated 
by PCR (Table B-1). False positive examples were selected representing 
different types of spurious fusions: e.g. overlapping genes, fusions involving 
highly expressed genes such as ribosomal proteins among others. 
 
An additional advantage of using a classifier to determine the potential 
true fusions, as opposed to hard filters defined a priori, is that we can learn those 
features or rules from the data itself. In our dataset, the top five features that 
contributed the most for the random forest classifier were, in decreasing order of 
importance, fusion type (Inter-chromosomal, Intra-chromosomal, Tandem-
duplication), sum of the median alignment quality of both gene partners, number 
of reads spanning and encompassing reads across the fusion junction and the 
cohort normalized expression value of the 3’ gene (Figure 3.4). 
 
Two additional sets of true fusions were left out of the training dataset to 
calculate the recovery rate. First, a set of 11 fusions called in the Seoul cohort23 
and validated by PCR by the same authors, and a second set of 15 fusions 
called in the UMICH cohort by THF, ChimeraScan, manually curated and 
validated by PCR. In the first of these datasets, our classifier recovered 10 out 11 
fusions for a 90.1% recovery rate (Table 3.3-1). In the second set, the classifier 






Table 3.3-1. Fusions recovered by our classifier in the Seoul cohort.  






























































































Seoul_lc_c25 3 6 ASCC3 UBE2E1 Seoul 1 5 9 9 18 16 2 9 InterC 1 
Seoul_lc_s11 11 11 C11orf93 HYOU1 Seoul 13 3 9 9 18 155 7 49 IntraC 1 
Seoul_lc_c25 1 6 CGA ZFYVE9 Seoul 15 4 9 9 18 16 3 12 InterC 1 
Seoul_lc_s18 19 19 DNM2 NMRK2 Seoul 8 2 3 3 6 3 1 1 IntraC 0 
Seoul_lc_s18 11 11 FGF3 RBM14‐RBM4 Seoul 1 2 9 9 18 20 1 8 IntraC 1 
Seoul_lc_c17 12 12 GPR133 TXNRD1 Seoul 16 14 9 9 18 14 2 10 IntraC 1 
Seoul_lc_s23 19 14 MBIP AXL Seoul 19 6 9 9 18 1566 153 1210 InterC 1 
Seoul_lc_s38 12 4 PDGFRA SCAF11 Seoul 15 2 9 9 18 132 13 110 InterC 1 
Seoul_lc_s9 10 6 ROS1 CCDC6 Seoul 5 9 9 9 18 77 6 53 InterC 1 
Seoul_lc_c36 12 12 SLC16A7 MUCL1 Seoul 2 3 9 9 18 82 7 16 IntraC 1 













Table 3.3-2. Fusions recovered by our classifier in the UMICH cohort.  
































































































A28 9 9 PTCH1 FAM120AOS umich  23 2 7 7 14 8 2 6 IntraC 1 
C028 1 1 WASF2 FGR umich  9 12 9 9 18 21 48 2 TD 1 
C074 8 8 GTF2E2 GSR umich  5 1 9 9 18 87 33 0 TD 1 
C004 3 3 HLTF HPS3 umich  18 11 9 9 18 40 7 37 TD 1 
A49 11 11 CPT1A HRASLS2 umich  6 3 9 9 18 105 13 115 IntraC 1 
C040 11 11 AHNAK KAT5 umich  6 6 6 6 12 9 43 6 IntraC 1 
H1838 6 6 PCMT1 LATS1 umich  3 6 9 9 18 15 6 7 TD 1 
A52 9 12 PTPRD LRMP umich  43 5 9 9 18 12 2 8 InterC 1 
C004 3 3 UBA5 MRAS umich  10 2 9 9 18 12 2 13 IntraC 1 
H1792 12 12 SRGAP1 MSRB3 umich  3 2 9 9 18 79 14 119 IntraC 1 
H23 2 2 THADA MTA3 umich  38 9 9 9 18 33 12 16 IntraC 1 
H441  1  1  MEAF6  SCMH1  umich  5  9  4  7  11  7  27  4  IntraC  1 
C051  15  15  MYO5C  TNFAIP8L3  umich  12  1  9  9  18  15  52  15  IntraC  1 
A25  3  3  IP6K1  TRAIP  umich  4  5  9  9  18  63  46  58  TD  1 






3.2.5 Mutation calling 
 
UMICH cohort: Single nucleotide variants (SNVs) were called using 
Varscan2 (Varscan2/2.2.8)48 on the ssRNAseq libraries of the UMICH cohort. 
Because, we did not have matched normal for each tumor sample, we consider 
only SNVs that were previously reported in the Catalogue of Somatic Mutations 
database (COSMIC version 56). Single nucleotide mutations in other positions 
were not considered for reporting or downstream analysis. SNVs present in 
dbSNP (v135) were filter out, as well as SNVs with variant fraction smaller than 
10%, or with less than six reads covering the position. Insertions and deletions 
were not called from the RNAseq data, because currently there are not available 
algorithms to efficiently assess these genetic aberrations on RNASeq libraries. 
SNVs for all tumor samples were aggregated and annotated using variant-
tools141.  
 
TCGA cohort: All somatic mutations both SNVs and indels called on 
Exome sequencing data for the TCGA consortium were extracted from 
aggregated Mutation Annotation Format (MAF) files available at the Broad 
institute firehose Genome Data Analysis Center MAF dashboard on May 11 of 
2013.  
 
Seoul cohort: All SNV and insertion/deletion somatic mutations reported 
by Seo et al (2012) were used23. 
 
3.2.6 Sample annotation 
 
We annotated the mutation status of oncogenes and tumor suppressor 
well known to be involved in lung adenocarcinoma and squamous carcinomas. 





HRAS, EGFR, BRAF, PIK3CA, and MET, while missense or non-sense 
mutations were considered for TP53, STK11, NF1, PTEN, SMARCA4, CDKN2A, 
and APC. Mutations reported in COSMIC were considered for AKT, MEK, ATM, 
AKT1, KEAP1, U2AF1, RBM10, ARID10, and MYC which have been recently 
implicated on these indications3,142. Finally, we used the somatic mutation 
information to divide the combined cohort in two groups: samples with known 
drivers and samples of unknown drivers. The first group corresponds to samples 
with somatic mutations in KRAS, NRAS, HRAS, EGFR, BRAF and/or PIK3CA, 
while the second group to samples that do not harbor alterations in those well-
known driver genes.  
 
3.3 Experimental methods 
3.3.1 Sample acquisition 
 
We collected tumor samples from 67 patients with lung adenocarcinomas 
and 36 patients with lung squamous carcinoma. Matched normal lung tissues 
samples were collected at the edge of cut lung lobe, as far as possible and at 
least 3 cm far away from tumor, following surgery at the University of Michigan. 
The recruitment of subjects and informed consent were reviewed and approved 
by our IRB. These tissues were preserved by flash freezing immediately following 
surgical resection, and clinical and follow-up data have been collected. None of 
the patients used in this study received preoperative chemotherapy or radiation 
therapy. The 24 cell lines included in this study were all acquired from The 
American Type Culture Collection (ATCC) and grown according to the ATCC 
suggested media conditions.  
 






Regions of tumor tissue containing a minimum of 70% tumor cellularity 
defined by cryostat sectioning were utilized for RNA isolation. Tissues or cell 
lines RNAs were isolated using miRNeasy mini kit (Qiagen). RNA quality was 
analyzed using the 2100 Bioanalyzer (Agilent Santa Clara, CA). Only samples 
with RNA integrity number (RIN) >8.0 were subjected to RNA sequencing. 
 
3.3.3 Preparation of RNASeq libraries 
 
Transcriptome libraries were prepared following a modified protocol 
previously described for generating strand specific RNASeq libraries24.  Briefly 
2.5 μg of total RNA was subjected to polyA selection using oligodT beads 
(Invitrogen, Carlsbad, CA).  Purified polyA RNA was fragmented and reverse 
transcribed using SupersciptII (Invitrogen, Carlsbad CA).  Second strand 
synthesis was performed with DNA Polymerase I (New England Biolabs, Ipswich, 
MA) in the presence of dNTP mix containing dUTP instead of dTTP.  The product 
was then subjected to end repair, A base addition and adaptor ligation steps.  
Libraries were next size selected in the range of 350 bps after resolving in a 3% 
Nusieve 3:1 (Lonza, Basel, Switzerland) agarose gel and DNA recovered using 
QIAEX II gel extraction reagent (Qiagen, Valencia, CA). Libraries were barcoded 
during the 14-cycle PCR amplification with Phusion DNA polymerase (New 
England Biolabs, Ipswich, MA) and purified using AMPure XP beads (Beckman 
Coulter, Brea, CA). Library quality was estimated with Agilent 2100 Bioanalyzer 
for size and concentration. The paired end libraries were sequenced with Illumina 
HiSeq 2000 (2x100 bases, read legth). Reads that passed the filters on Illumina 
BaseCall software were used for further analysis.     
 
3.3.4 PCR fusion validation 
 
We validated a subset of nominated fusion genes by THF from UMICH 





2 had inconclusive results and 1 was not validated, representing a validation rate 
of 89%. 
 
3.3.5 RNA isolation, cDNA synthesis and quantitative RT-PCR 
 
Total RNA was isolated using either QIAzol reagent or RNAeasy micro kit 
(QIAGEN, Valencia, CA).  cDNA was synthesized from total RNA using 
Superscript III in presence of random primers (Invitrogen, Carlsbad, CA). 
Quantitative Real-time PCR (qPCR) was performed using SYBR Green Master 
mix on the StepOne Real-Time PCR System (Applied Biosystems). All 
oligonucleotide primers for the qPCR assays were obtained from Integrated DNA 
Technologies (Coralville, IA); NRG1 forward 
5’GATTCCTACCGAGACTCTCCTC3’ and reverse 
5’TGGAAGGCATGGACACCGTCAT3’ and GAPDH forward 
5’GTCTCCTCTGACTTCAACAGCG3’ and reverse primer 
5’ACCACCCTGTTGCTGTAGCCAA3’. Fold changes were calculated relative to 
GAPDH and normalized to the non-targeting control. 
 
3.4 siRNA knockdown studies 
 
Lung cancer cell line NCI-H1793 were plated in 6-well plates at a desired 
numbers and transfected with 2 nmol of NRG1 siRNAs (J-004608-11; and J-
004608-12) or non-target control siRNA (Thermo Scientific). Transfection with 
oligofectamine reagent (Invitrogen, Carlsbad, CA) was performed twice over a 
period of 48 hours.  Knockdown efficiency was determined by qPCR.  Cell 
proliferation assessed by Incucyte, 24 hours after transfection, cells were 
trypsinized and plated in triplicate at 8,000 cells per well in 24-well plates. The 
plates were incubated in the IncuCyte live-cell imaging system (Essen 
Biosciences) at 37°C with 5% CO2 atmosphere. Cell proliferation rate was 






3.4.1 Cloning and expression of CD74-NGR1 fusions and cell proliferation 
and migration assays 
 
CD74-NRG1 fusion transcript was amplified from the Index lung cancer 
sample tissue cDNA with forward 
5’CACCATGCACAGGAGGAGAAGCAGGAGCTGT3’ and reverse primers 
5’TTCAGGCAGAGACAGAAAGGGAGTGGA3’ using Hi-fidelity polymerase 
(Qiagen, Valencia, CA). The PCR product was gel purified and cloned into plenti-
TOPO cloning vector (Invitrogen, Carlsbad, CA) and the DNA sequence was 
independently verified by Sanger sequencing.  The control LacZ or C-terminal V5 
tagged CD74-NRG1 constructs were transfected into the normal lung epithelial 
cell line BEAS-2B cells. The stable cells generated after selection in BEBM 
media (Lonza, Basel, Switzerland) containing 3 micrograms of blasticidin 
(Invitrogen, Carlsbad, CA). For proliferation assays, 50,000 cells were plated in 
12-well plates and grown in regular media. Cells were harvested by trypsinization 
and counted manually at indicated time points. All assays were performed in 
quadruplicates. For migration assays, stable cells were re-suspended in medium 
without growth factors, then seeded at 50,000 cells per well into Boyden 
chambers (8 μm pore size, BD Biosciences) and were incubated for 24 hours in a 
humidified incubator at 37°C, 5% CO2 atmosphere. The bottom chamber 
contained medium with growth factors as chemo-attractant. The top non-
migrating cells were removed with a cotton swab moistened with medium and the 
lower surface of the membrane was stained with Diff-Quick Stain Set (Siemens). 
The number of cells migrating to the basal side of the membrane was visualized 
with an Olympus microscope at 20x magnification. Pictures of five random fields 
from 4 wells were obtained and the number of cells stained manually quantified.   
 






Cells were plated in 100 mm plates and incubated at 37ºC in 5% CO2 
overnight to allow cells to adhere. Cells were washed with ice cold PBS twice. 
Whole-cell extracts from treated or untreated cell lines were harvested using cell 
lysis buffer (Cell Signaling), according to the manufacturer’s protocol. Protein 
concentrations in cell lysates were measured using the protein assay 
quantification (bicinchoninic) (Pierce, Rockford, IL). Equal amounts of protein 
were loaded in each lane. Cell lysates were resolved under reducing conditions 
by 10% SDS-PAGE and then transferred to PDVF membranes. After being 
blocked with 5% milk in tris-buffered saline (TBS) with 0.1% Tween20, the 
membranes were incubated with antibodies against activated or total forms of 
protein overnight at 4°C, washed three times with 0.1% Tween 20 - TBS and 
then incubated for 60 minutes with 2000:1 peroxidase-conjugated anti-rabbit IgG. 
Antibodies against E-Cadherin, Vimentin, phospho-Erbb3, phospho-Erbb3, 
phosho-ERK and total-ERK were purchased from Cell Signaling Technology Inc. 
(Beverly, MA). Total Erbb3 and Erbb4 were purchased from Santa Cruz 
Biotechnology Inc. (Dallas, TX). The membrane-bound peroxidase activity was 
detected using ECL Prime Western Blotting Detection kits (Amersham, Arlington 
Heights, IL) and chemiluminescent images were captured by exposing film.  
 
3.4.3 Chemicals and cell proliferation assays 
 
Two MEK inhibitors (AZD6244 and GSK1120212), an EGFR/ERBB2 
inhibitor (Afatinib) and a MET/ALK inhibitor (Crizotinib) were obtained from 
SelleckChem. The effect of these drugs on proliferation of NCI-H1793, NCI-
H1299 and NCI-H1792 was measured. Cells were plated at 1.5 – 2.5 × 103 
cells/well in 100µl of appropriate culture medium using 96-well plates and 
incubated at 37ºC in 5% CO2 overnight and then treated 24 hours later with the 
respective drugs. Each inhibitor was prepared at 7 serial dilutions ranging from 
0.03 to 30µM at the final concentration. On day 3, cell viability was assessed 





instructions. The absorbance at 450 nm and reference at 630 nm were measured 
using an automated plate reader (ELx808 Bio-Tek) at different time-points. Cell 
proliferation was estimated by dividing the mean absorbance of the treatment 
group divided by the mean absorbance of the vehicle-treated control X 100%. 




3.5.1 Patient cohort description 
 
We have assembled a cohort of 732 patient samples, which includes lung 
adenocarcinoma and squamous carcinoma patients, by combining our UMICH 
cohort with public available data from TCGA and the recently published cohort by 
Seo et al., 201223 (from here on the Seoul cohort).  
  
We sequenced mRNA from 133 samples by using strand specific RNA 
paired-end sequencing (ssRNASeq) technology. The UMICH cohort includes 67 
LUAD, 36 LUSC, 24 lung cancer cell lines and 6 matched nonmalignant lung 
samples. Moreover this cohort included 64 stage I, 17 stage II and 22 stage III 
patients. Eighty-nine patients were smokers, whereas 8 were never-smokers and 
in 4 cases the smoking status was unknown. The median smoking pack years 
was 45 (range, 2 – 300) and practically all patients were heavy smokers (more 
than 10 pack years). The average follow up was 5.05 years. Sample acquisition 
details were described provided in the methods section. The TCGA cohort used 
in this study encompasses 305 LUAD and 216 LUSC samples. This includes 250 
stage I, 112 stage II, 101 stage III, and 19 stage IV cases as well as 39 with 
unknown stage. This cohort includes 4 never-smokers, 20 light smokers (defined 
by less than 10 pack years of tobacco use) and 365 heavy smokers (more than 
ten pack years of tobacco smoking), and the average follow up was 1.72 years. 





clinical information. The Seoul cohort includes 79 matched normal samples; 
fusions called in these normal samples were used for filtering as described in the 
methods. 
 
In summary, the combined cohort used in this study includes 451 lung 
adenocarcinomas, 251 lung squamous carcinomas and 24 NSCLC cell lines, 
making this the most comprehensive RNA-Sequencing cohort of lung cancers 
assembled so far. A summary of the Clinic-pathological characteristics is 
provided in Table 3.3-3. 
 
Table 3.3-3. Clinic-pathological characteristics of the combined lung cohort used in this study. 
SAMPLES 
LUAD LUSC LUCL TOTAL 
UMICH 67 36 24 127 
SEOUL 79 0 0 79 
TCGA 305 216 0 521 
TOTAL 451 251 24 727 
SEX 
MALE FEMALE 
UMICH 56 55 
SEOUL 48 31 
TCGA 298 223 
TOTAL 402 309 
FOLLOW UP TIME 
MIN MEDIAN MAX AVAILABLE
UMICH 0.26 4.6411 17.3726 111 
SEOUL NA NA NA 0 
TCGA 0 0.9233 18.6630 436 
TUMOR STAGE 
STAGE I STAGE II STAGE III STAGE IV 
UMICH 64 17 22 0 
SEOUL NA NA NA NA 
TCGA 250 112 101 19 
SMOKING 
NEVER LIGHT HEAVY 
UMICH 8 NA 89 
SEOUL NA NA NA 







3.5.2 Global overview of the fusions’ landscape 
 
Fusion calling has lagged behind single nucleotide variant calling, and 
currently there are not best practices for fusion identification, removal of false 
positives neither benchmarking comparison of different algorithms on public 
available dataset with golden truth positives. In order to have comparable results 
among samples and cohorts it is important to develop unified and data driven 
fusion prediction pipelines. We used the workflow described in Figure 3.1 (See 
Methods) to identify fusions, quantify the total number of observed fusions in 
each of patient, and integrate mutation and clinical data for each of the 732 
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We detected an average of 13 fusions per tumor sample (range, 0 - 67). 
Although, both lung adenocarcinoma and squamous carcinoma have similarly 
high single nucleotide mutation rate of about 8.1 mutations/Mb3,130, they showed 
different average number of fusions per sample. We observed an average of 11 
fusions in lung adenocarcinoma tumors, while 17 in squamous carcinoma 
(student t-test p-value < 2.2 x 10-16). Moreover, we did not observe statistically 
significant differences on the average number of fusions between heavy and light 
smokers (LUAD student t-test p-value= 0.75; LUSC student t-test p-value=0.42); 
nor among different clinical stages regardless of the tissue type (Table B-2, Table 
B-3). However, we did find that tumors harboring missense or nonsense 
mutations in TP53 showed greater average number of fusions as compared to 
samples with TP53 wild type (Supplementary Figures 1a, 1b, p-value = 0.0012). 
Because > 80% of lung squamous carcinomas have somatic mutations in TP533; 
that difference is consistent with the one observed on the average number of 
fusions between LUAD and LUSC carcinomas.  In LUAD, we also observed a 
significant correlation among the presence of oncogenic mutations (e.g. KRAS 
activating mutations) and TP53 deleterious mutations (stop codon or splice site 
mutations), and the number of fusions (Fisher’s exact test p-value=0.0089). This 
correlation could not be tested in LUSC because in this indication there were a 
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A) Kaplan-Meyer survival curve for the combined cohort samples with low (0-7), intermediate (8-16), or high 
(≥17) number of fusions (p-value=p=0.0089).  Samples with high number of fusions have worst prognosis 
(Cox survival analysis p-value=0.0053) B) Kaplan-Meyer survival curve for LUAD samples with low (0-6), 
intermediate (7-12), or high (≥13) number of fusions (p-value=0.076).  Samples with high number of fusions 
have worst prognosis (Cox survival analysis p-value=0.029) b) Kaplan-Meyer survival plot for LUSC samples 
with low (0-11), intermediate (12-18) and high (≥19) number of fusions (p=0.169). Samples with high number 
of fusions have worst prognosis (Cox survival analysis p-value= 0.0717).  
 
Statistically significant clinical covariates in the univariate Cox model 
(Table 3.3-4) were used in a multivariate analysis examining the prognostic value 
of number of fusions.  
 




HR 95% CI p-value 
Age, continuous 1.03 1.01 – 1.04 < 0.001 
Sex   
Female 1.00 -- 
Male 1.33 1.02 – 1.74 0.037 
Stage, continuous  1.55 1.35 – 1.76 < 0.001 
Smoking status   
Non-smoker 1.00 -- 
Smoker (<35 pack-year) 1.31 0.52 – 3.30 0.565 
Smoker (≥35 pack-year) 1.49 0.61 – 3.67 0.378 
Histology    
Adenocarcinoma 1.00 --  
Squamous cell 
carcinoma 0.99 0.76 – 1.29 0.989 
TP53 status    
   Wild-type 1.00 --  
    Mutant 0.94 0.66 – 1.33 0.717 
KRAS status    
Wild-type 1.00 --  
Mutant 0.94 0.66 – 1.33 0.717 
EGFR status    
Wild-type 1.00 --  
Mutant 1.01 0.77 – 1.33 0.924 
 
Strikingly, high number of fusions was independently associated with 
worse overall survival (HR = 1.56, 95% CI 1.13 – 2.15, p-value = 0.007, Table 





TP53, KRAS and EGFR or smoking status were included in the analysis, number 
of fusions remained independently associated with worse outcome as well (p-
value =0.005).  
 
 
Table 3.3-5. Multivariate Cox regression for overall survival according to number of fusions in 621 
NSCLC patients adjusted by age, gender and stage. 





Age, continuous  1.04 1.02 – 1.05 <0.001 
Gender Female 1.00 –  
0.270 Male 1.17 0.89 – 1.54 
Stage, continuous 1.64 1.43 – 1.88 <0.001 
Number of fusions Low 1.00   
 
0.007 
Intermediate 1.11 1.78 – 1.59 
 High 1.56 1.13 – 2.15 
 
 
3.5.4 Lung fusions landscape is dominated by low recurrence and private 
fusions 
 
In order to prioritize fusion candidates and discriminate potentially true 
fusions from spurious ones, we developed a classifier to distinguish potentially 
genuine fusions from false positive ones (See Methods). This classifier uses 
structural and functional annotation features of each fusion in order to predict 
whether a fusion is potentially genuine or not.   
 
Remarkably, our classifier has a recovery rate greater than 90% and it 
automatically recapitulates our intuitive knowledge about the important structural 
properties defining bona fide fusions (Methods). In our fusions’ dataset, the top 














































































































































sequence is preserved). Given the size of our cohort, we could better estimate 
the recurrence of different gene fusions and so we distinguish between three 
types of recurrence: molecular, functional and family recurrence. Molecular 
recurrence refers to fusions in which the same 5’ and 3’ partners are observed in 
different samples such as SLC34A2-ROS1; functional recurrence refers to cases 
in which either the 5’ or 3’ partner is the same (CCDC6-RET and KIF5B-RET); 
and gene family recurrence correspond to gene fusions in which 5’ or 3’ partner 
belongs to the same gene family (FGFR3-TACC3, FGFR2-CCDC6, BAG4-
FGFR1). Functionally recurrent kinase fusions ROS1, RET and ALK were found 
on 0.86%, 0.29%, and 0.14% across this combined cohort (Table B-4,Table B-5). 
Other functionally recurrent gene fusions include BCAS3-MAP3K3, MRC2-
MAP3K3; and GOSR1-NF1 and NLK-NF1 and NF1-PSMD11. The recurrent 
gene fusions involving the tumor suppressor Neurofibromin 1 (NF1) do not 
generate productive fusion proteins (GOSR1-NF1, NLK-NF1, NF1-PSMD11) and 
instead destroy the functional activity of NF1, suggesting that this could be an 
additional mechanism for NF1 inactivation in lung cancers. NF1 inactivation leads 
to activation of the PIK3CA pathway. 
 
Our results confirm the high heterogeneity and low recurrence of lung 
cancer fusions, as most fusions found were private fusions or appeared at very 
low frequency (Fusions Table and Table B-4,Table B-5)).  
 
Although present in a small percentage of patients, known targetable 
fusions are preferentially observed in samples lacking any other known 
oncogenic drivers. We therefore determine for each sample in our combined 
cohort the mutation status of well-known oncogenes and tumor suppressor 
playing a role in lung cancers (Methods), reproducing previous results about the 
mutational landscape of LUAD and LUSC (Figure 3.5) and confirming that known 
fusions involving ROS1, RET and ALK are exclusively found in samples without 
other oncogenic drivers. In this set of samples the frequency of those fusions 





combining mutational and fusion status with gene expression also showed that 
for fusions such as ROS1 in some index samples the expression of the fusion 
kinase was an outlier across the combined cohort (e.g., 3 out 6 in ROS1). 
Interestingly, we also identified the presence of samples with outlier expression 
of ROS1, and FGFR3 almost exclusively in samples without other oncogenic 
drivers (Fisher exact test p-values= 0.0048 and 0.0864 respectively, Figure 3.5). 
While the mechanism of overexpression remains to be delineated, the outlier 
kinase expression may have a potential driving role and this patient subset may 
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A) Lung adenocarcinoma (LUAD, n=451). B) Lung squamous carcinoma (LUSC, n=251). Top panel: 
Histograms represent the number of high quality fusions identified in each sample. Central Panel: Heatmap 
denotes the presence or absence of activating mutations in known oncogenes (red) and deleterious 
mutations in tumor suppressors (blue). Samples are presented in columns and genes are presented in rows. 
Right middle panel: Bar plot summarizes the number of samples harboring activating or deleterious 
mutations for each gene. Bottom Panel: Heatmap displays samples harboring both known and novel gene 
fusions (green) involving either receptor kinase genes or NRG1. Samples in red indicate outlier expression 
pattern observed in the respective genes. The ordering of samples in center panels was dictated by 
mutation status in KRAS, NRAS, HRAS, EGFR, BRAF, PIK3CA, and TP53 genes in that order. Remarkably, 
NRG1 gene fusions were observed in samples that lack other driver events similar to the RTK fusions 
involving ROS1, RET, ALK and FGFR3 genes. The NRG1 fusion index samples exhibited outlier NRG1 
expression and the outlier samples harbored no other known driver events in both LUAD and LUSC. 
 
3.5.5 Recurrent NRG1 fusions in lung cancers 
 
Remarkably, we found a novel functionally recurrent gene fusion where 
the common 3’-gene Neuregulin 1 (NRG1) was fused to different 5’ partners 
(Figure 3.6a). The gene fusions, CD74-NRG1, RBPMS-NRG1 and WRN-NRG1, 
occurred in both LUAD and LUSC samples. While both CD74-NRG1 and 
RBPMS-NRG1 fusion events resulted in the production of chimeric fusion 
proteins, the WRN-NRG1 fusion results in the overexpression of full length NRG1 
controlled by the WRN gene promoter. As a member of EGF family of ligands, 
the growth factor NRG1 transduces its signal through the HER/ErbB receptor 
tyrosine kinases143,144. NRG1 protein contains various domains such as kringle 
like, immunoglobulin like domains and the EGF domain that is located in the C-
terminal region143.  Notably the EGF domain that is essential for receptor 
interaction145 is preserved in all the NRG1 fusions identified (Figure 3.6a). All 
NRG1 fusion index samples were found in the driver negative group (0.78% 
frequency) and displayed outlier expression of NRG1 specifically in the tumor 
sample and not in the matched normal tissue (Figure 3.6b and Figure 3.6c). 
Strikingly similar to the pattern described above for known kinases fusions such 
as ROS1.  Therefore, we reason that NRG1 overexpression could be implicated 
in its dysregulation. Among all samples in our combined cohort, the driver 
negative lung cancer cell line H1793 exhibited the highest expression of NRG1 
(more than 250 FPKM) (Figure 3.6d), but no NRG1 fusion was detected either by 





to siRNA mediated gene knock down. A 70% knock down achieved with two 
independent NRG1 siRNAs (Figure 3.6e) affected cell proliferation rate as 
indicated by cell growth assay (Figure 3.6f). Outlier NRG1 expression was also 
observed in 10 other driver negative samples (Table 3.3-6), elevating the 
frequency of samples with NRG1 dysregulation to 13/314 (4.14% recurrence in 
the driver negative group) implicating a potential causal role for NRG1 in this 
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Table 3.3-6. Lung cancer samples harboring fusions and/or outlier expression of NRG1. 








A35 umich LUAD YES NO 
TP53 p.P33R p.P72R;  RBM10 p.A630P 
p.A696P;  SMARCA4 p.R513W;  APC 
p.V1822D p.V1804D; ATM p.N1983S 
99% 29.08 0.9273 
lc_s17 seoul LUAD YES NO TP53 p.PXXXR 99% 33.08 0.9273 




SMARCA4 p.E1056X; TP53 p.R248L p.R209L;  
APC p.V1822D p.V1804D; ATM p.N1983S; 
99% 83.92 0.9273 
0232d299-4cdf-4fd7-




TP53 p.R156P; KEAP1 p.D236N; RBM10 
p.S781L;  
99% 21.32 0.9273 
7b0622ab-63ea-483f-
ae40-d3ea587bdbba tcga LUAD 
NO/
TBD
NO - 99% 25.86 0.9273 




SMARCA4 p.E514X; TP53 p.P33R p.R141H; 
APC p.V1822D p.E1991D;  EGFR p.C311F; 
ATM p.N1983S;  
99% 281.86 10.1265 
a3e1ac67-a1f2-44fb-8343-
a7e8239fc24a tcga LUSC YES NO TP53 p.G244C;  PIK3CA p.D1045V 99% 49.5573 4.2247 
ce8612ab-3149-4a6a-




TP53 p.S314fs; CDKN2A p.P3fs; APC p.S966G; 
NF1 p.E1734V. 
99% 34.5314 4.2247 
7e691df8-8ea6-472c-86bf-




APC p.S966G; CDKN2A p.P3fs; TP53 p.S314fs; 
NF1 p.E1734V 
99% 49.3324 4.2247 
791f1b21-695e-4db1-
b41d-80590c09d257 tcga LUSC 
NO/
TBD
NO KEAP1 p.R320Q p.R470C; PIK3CA p.E453K 99% 31.2416 4.2247 
14a4a93a-e24d-46f2-
bee3-18bd792ef95a tcga LUSC 
NO/
TBD
NO TP53 p.E271* 99% 36.7394 4.2247 
6394fe4a-6034-4c79-b28f-
aa43e3753730 tcga LUSC 
NO/
TBD





In addition to characterizing NRG1 fusions, we used normal lung BEAS-
2B cells to generate stable overexpression of CD74-NRG1 fusion protein. Fusion 
overexpression significantly increased both cell proliferation (Figure 3.7a) and 
migration (Figure 3.7b, Figure 3.7c) and induced a notable phenotypic alteration 
in cell shape (Figure 3.7d). Western blot analysis revealed evidence for epithelial 
mesenchymal transition (EMT) upon CD74-NRG1 overexpression as supported 
by increased vimentin protein expression (Figure 3.7e). In order to identify 
potential pathways activated by the CD74-NRG1 fusion, we performed gene 
expression microarray profiling of CD74-NRG1 and LacZ clones. Significant 
analysis of microarrays (SAM) shows vimentin as one of the top overexpressed 
genes in CD74-NRG1 confirming the western blots (Figure B.1), as well as, down 
regulation of cadherins, supporting the hypothesis of EMT in CD74-NRG1 
positive cells. Gene set enrichment analysis identified down regulation of cell 
adhesion pathways (Figure B.1) and, interestingly, up-regulation of SRC (Figure 
3.7f) and ERBB  (Figure 3.7g) pathways in CD74-NRG1 cells. In light of these 
results we assessed the activation of those pathways by western blot and 
confirmed that, compared to LacZ control, the CD74-NRG1 cells showed 
substantially increased levels of phosphorylated ERBB3 and phosphorylated 
JNK, while a modest increase in phospho-ERK (Figure 3.7h). Having functionally 
characterized CD74-NRG1 fusion in lung cancers, we looked for productive and 
outlying NRG1 fusions in other cancer types and found the presence of 
RAB2IL1-NRG1 in ovarian cancer. As noted in the lung cancer fusions, functional 
EGF domain is retained in RAB2IL1-NRG1 and the fusion index case exhibited 
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membrane after Diff-Quick staining with an Olympus microscope at 20x magnification. C) Cell counting for 
cells migrating through the Boyden chamber membrane after 24 hours. BEAS-2B cells expressing CD74-
NRG1 fusion showed a higher migration rate as compared to Lac-Z (=0.0014). D) Representative pictures of 
BEAS-2B cells expressing the CD74-NRG1 fusion or Lac-Z. Cells expressing the CD74-NRG1 fusion 
appeared smaller and more fusiform as compared to Lac-Z, suggesting that they acquired a more 
mesenchymal phenotype. E) Western blot analysis of V5 Tag, E-cadherin (CDH-1) and Vimentin in 
transfected BEAS-2B cells. V5 Tag was expressed only in CD71-NRG1 transfected cells, which showed a 
slightly lower expression of CDH-1 and a significant increase of Vimentin expression. F,G) Gene set 
enrichment analysis based on differentially-expressed genes among BEAS-2B cells transfected with the 
CD74-NRG1 fusion or Lac-Z. Significant up-regulation of SRC and ERBB2 pathways was observed in 
CD74-NRG1 cells. H) Western blot analysis of ERBB3, ERK and JNK1 activation. CD74-NRG1 cells 
showed a noticeably activation of ERBB3 and JNK1 as compared to Lac-Z cells, whereas ERK activation 




Treatment and diagnosis of NSCLC, especially LUAD, has been 
transformed by the use of targeted therapies and companion diagnostics tests. 
For example, EGFR activating mutations in exons 18, 19 and 21 are now 
routinely assessed before recommending treatments with Gefitinib and Erlotinib; 
as the response rate is close to 70%146 in the mutation positive subpopulation of 
advanced NSCLC. More recently, fusions involving tyrosine kinases such as 
ROS1, ALK and RET8,132,147 have been identified primarily in young lung 
adenocarcinomas patients with no other driver mutations and no history of 
tobacco smoking. Despite the low frequency of those fusions in the population, 
phase I clinical trials have shown that patients with EML4-ALK fusions respond 
well to Crizotinib148,149 a drug targeting ALK, demonstrating the efficacy of 
targeting these kinases in the rearrangement positive subpopulation of patients. 
In this study, we use RNA sequencing to characterize, in an unbiased manner, 
the fusions’ landscape of lung adenocarcinoma and lung squamous carcinoma 
indications in order to identify potentially new oncogenic fusions. 
 
We showed that the fusions landscape is highly heterogeneous and 
dominated by low recurrence and private fusions (Figure 3.5); with on average 
higher number of fusions per sample being observed in LUSC than LUAD (t-test 





any other clinical characteristics such as smoking history or disease stage (Table 
3.3-4). We also found that tumors harboring missense or nonsense mutations in 
TP53 have greater average number of fusions than TP53 wild type, although this 
result is potentially confounded by the high prevalence of TP53 mutations in 
squamous carcinomas. Remarkably, high number of fusions was independently 
associated with worse overall survival (Table 3.3-5, Figure 3.3), after adjusting 
for gender, disease stage and mutation status of TP53, KRAS and EGFR. As 
RNA sequencing becomes widely adopted for profiling transcript expression and 
gene fusions, our results suggest that the number of fusions could be used as an 
independent prognostic marker in lung cancers. 
 
The recurrent tyrosine kinase fusions, previously reported, are found 
almost exclusively in driver negative lung adenocarcinomas, and have not been 
reported in squamous carcinoma. Here, we found recurrent fusions involving 
3’gene Neuregulin 1 (NRG1) (CD74-NRG1, RBPMS-NRG1 and WRN-NRG1) 
and NRG1 outlier expression in both LUAD and LUSC indications (Figure 3.6). 
NRG1, a growth factor receptor that transduces its signal through the HER/ErbB 
receptor tyrosine kinases pathway, is expressed in a subset cancers, namely 
breast, lung and others150. CD74 is a known 5’-fusion partner in lung cancer 
involved in ROS1 kinase fusions. While CD74-NRG1 and WRN-NRG1 fusions 
contains the signal peptide and type II transmembrane domain to locate NRG1 in 
the plasma membrane, cellular location of RAB2IL1-NRG1 and RBPMS-NRG1 
needs to be further characterized.  Nevertheless, it has been previously reported 
that of the 20 NRG1 transcript variants (several transcripts lack the N-terminal 
signal sequence required for transport to extracellular space and for membrane 
localization. In these instances an internal hydrophobic amino acid stretch is 
speculated to substitute the N-terminal signal sequence143,145. 
 
Remarkably, NRG1 fusions are present in samples with no other driver 
events (Table 2, Figure 3) and the index samples display outlying expression of 





Moreover, we also found 10 additional cases of outlying NRG1 expression in 
driver negative samples, suggesting NRG1 potential role as a driver on those 
samples. We demonstrated that abrogating NRG1 outlying expression affects 
cell proliferation (Figure 3.6) and more importantly we showed that the fusion 
construct (CD74-NRG1) increased proliferation and migration in cell line models 
(Figure 3.7). Taken together, NRG1 fusions and outlying expression of NRG1 
account for 4.14% of the driver negative lung cancer patients. 
 
The therapeutic potential of NRG1-ERBB autocrine loop has been 
previously suggested151 and more recently blocking NRG1 and other ligand-
mediated Her4 signaling were shown to be useful in enhancing the magnitude 
and duration of the chemotherapeutic response of NSCLC152. Further studies of 
the therapeutic opportunities for LUAD and LUSC patients with NRG1 
rearrangements are warranted. 
 
In conclusion, the previously documented success of targeted therapies 
against low recurrence oncogenic fusions in lung cancer and the high 
heterogeneity of the fusions’ landscape, shown in this study, reinforce the 
demand for more personalized and tailored drug therapies for this disease. 
 
3.7 Contributions 
Science is a collective enterprise and it is much more fun when done with 
friends and good collaborators. The results presented in this chapter were made 
possible for the great collaboration and support of a team of people in the 
Chinnayian and Nesvizhskii labs. 
 
O. Alejandro Balbin: Omics data integration, RNASeq data processing, 
development of fusion classifier, fusions database, mutation analysis, additional 
bioinformatics and clinical analysis, NRG1 functional experiments design. 





specific libraries for the UMICH lung cohort, CD74-NRG1 construct and 
transfection, ORFs construction of the NRG1 fusion proteins, NRG1 functional 
experiments design. Manuscript writing. Ernest Nadal: Functional 
characterization of the CD74-NRG1 fusion protein, proliferation and invasion 
assays for BEAS-2B transformed cells with CD74-NRG1, clinical analysis, 
Western blots for JNK and ERBB3 activation. Manuscript writing. Guoan Chen: 
Tissue collection and PCR gene fusion validation. Matthew Iyer: RNASeq data 
processing. Dan Robinson: RNA Sequencing. Xuhong Cao: RNA Sequencing. 
David Beer: Experiment design and overall scientific project oversee. Arul M. 























Chapter 4  
Antisense gene expression in human cancers: 





High throughput RNA sequencing has revealed widespread transcription 
in the human genome153. However, the extent to which both DNA strands 
(forward and reverse) are transcribed in regions of the genome with overlapping 
genes is less well characterized. This lack of understating is in part due to the 
fact that initial RNASeq protocols did not preserve the strand of the original RNA. 
Overlapping transcripts originating from the same locus of DNA but on opposite 
strands are known as sense-antisense transcript pairs (S-AS) and they have 
been described in eukaryotes and bacteria. Natural antisense transcripts (NATs) 
are transcribed from the opposite strand to that of the sense transcript of either 
protein-coding or non-protein-coding genes154,155. In this study, the originally 
annotated transcript will be considered as the sense transcript and the more 
recently identified one on the opposite strand as the antisense transcript, 
following Pelachano and Steinmetz (2013)155. 
 
4.1.1 Natural antisense transcripts classification 
 
NATs may arise from independent transcriptional units including cryptic 
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4.1.3 Antisense expression 
 
Several attempts to describe the patterns and magnitude of antisense 
expression suggested that antisense expression might be far more extensive 
than previously anticipated; with 10-20% of loci exhibiting antisense expression 
in humans176, though up to 72% in mice177. However, previous studies attempting 
to characterize the magnitude of antisense expression used methods such as 
ASSAGE 4  176 or SAGESeq 5  for identifying NATs and quantifying antisense 
expression. These methods are intrinsically limited in their accuracy and 
coverage of the entire transcriptome, allowing only the assessment of a small 
fraction of the total number of genes and missing transcripts expressed at low 
levels. Due to these limitations and their laborious experimental protocols, those 
methods have been applied only to small datasets. This has limited our 
understanding of the landscape of antisense expression, the patterns of 
expression between overlapping transcripts and more importantly the role of 
antisense expression in cancer.  
 
4.1.4 Strand specific RNA sequencing 
 
RNA sequencing (RNASeq) has opened the way for a comprehensive 
analysis of the entire transcriptome. However, standard libraries for RNASeq do 
not preserve the information about which DNA strand was originally transcribed. 
This information is lost during the synthesis of randomly primed double stranded 
cDNA followed by addition of adaptors for next-generation sequencing24. In some 
cases, the strand is inferred by computational methods relying in known open 
reading frames and splice-site orientation in eukaryotic genomes, but these 
                                            
4 ASSAGE: asymmetric strand-specific analysis of gene expression 





methods are not able to accurate resolve the expression of locus with 
overlapping genes. 
 
Strand specific RNA sequencing (ssRNASeq) solves those problems by 
providing direct information on the DNA strand that was originality transcribed. 
Several methods for strand specific RNA library preparation has been proposed, 
but dUTP second strand labeling and the illumina RNA ligation are the leading 
protocols for ssRNASeq (see Chapter 1)24. ssRNASeq enhances the value of 
RNASeq experiments by allowing an accurate characterization of antisense 
transcripts, demarcation of the exact boundaries of adjacent genes in opposite 
strands and accurate resolving the expression of overlapping transcripts.  
 
4.1.5 Aims of this study 
 
In this study we use strand specific RNA paired-end sequencing 
(ssRNASeq) to comprehensively characterize the landscape of antisense 
expression. We applied ssRNASeq on a cohort of 376 patients including 9 
different cancer tissue types, making this the biggest cohort of ssRNASeq data 
assembled so far. Our results reveal that greater than 60% of human annotated 
transcripts have measureable expression coming from the opposite strand of the 
DNA. We also demonstrate that cis-NAT gene pairs have in general a positive 
correlation between their levels of expression, and that this pattern is stronger for 
head-to-head overlapping pairs. Moreover, by analyzing CpG islands localization 
with respect to the regions of overlap between transcripts, we suggest that the 
high gene expression correlation of HTH pairs would reflect shared bidirectional 
promoters between the sense and antisense transcripts.  
 
Furthermore, according to the expression across tissues, four groups of 
antisense loci were identified: tissue-specific, tissue-enriched/non-specific, 





study creates and makes available a catalogue of tumor suppressors and 
oncogenes with significant antisense expression (oncoNATdb), which will allow 




4.2.1 Bio-repository description 
 
The Michigan Center for Translational Pathology (MCTP) strand specific 
RNASeq repository included in this study has 376 samples. Most of the samples 
correspond to cancer tissues, being the largest tissue cohorts: breast, lung 
adenocarcinoma, lung squamous carcinoma, prostate cancer, ovarian cancer, 
pancreatic cancer, meningioma, rare cancers, and lung cell lines. Table 4.4-1 





















Table 4.4-1.Tissues and number of samples the MCTP ssRNASeq cohort.  
Major Cohorts 
Tissue Abbreviation Number of samples 
Breast cancer BRCA 66 
Lung adenocarcinoma LUAD 66 
Lung squamous carcinoma LUSC 37 
Lung cell lines LUCL 31 
Prostate cancer PRCA 27 
Ovarian cancer OVARIAN 23 
Pancreas cancer PANC 17 
Meningioma MENINGIOMA 13 
Rare cancers RARE  39 
Minor Cohorts 
Tissue Abbreviation Number of samples 
Cholangiocarcinoma CHOLANGIO 8 
Lung large cell carcinoma LULC 8 
Merkel cell carcinoma MERKEL 8 
Lung match normals LUNO 7 
Sarcomas SARCOMA 7 
Osteosarcoma OSTEOSARCOMA 5 
Adrenocortical carinoma ADRENOCORTICAL 4 
Hodgkin’s lymphoma  HODGKINS 4 
Rhabdomyosarcoma RHABDOMYOSARCOMA 3 
Combined Cohort  376 
 
4.2.2 Preparation of RNASeq libraries 
 
Transcriptome libraries were prepared following a modified protocol 
previously described for generating strand specific RNASeq libraries24.  Briefly 
2.5 micrograms of total RNA was subjected to polyA selection using oligodT 
beads (Invitrogen, Carlsbad, CA).  Purified polyA RNA was fragmented and 
reverse transcribed using SupersciptII (Invitrogen, Carlsbad CA).  Second strand 
synthesis was performed with DNA Polymerase I (New England Biolabs, Ipswich, 
MA) in presence of dNTP mix containing dUTP instead of dTTP.  The product 
was then subjected to end repair, A base addition and adaptor ligation steps.  





Nusieve 3:1 (Lonza, Basel, Switzerland) agarose gel and DNA recovered using 
QIAEX II gel extraction reagent (Qiagen, Valencia, CA). Libraries were barcoded 
during the 14-cycle PCR amplification with Phusion DNA polymerase (New 
England Biolabs, Ipswich, MA) and purified using AMPure XP beads (Beckman 
Coulter, Brea, CA). Library quality was estimated with Agilent 2100 Bioanalyzer 
for size and concentrations.  The paired end libraries were sequenced with 
Illumina HiSeq 2000 (2x100 bases, read length). Reads that passed the filters on 
Illumina BaseCall software were used for further analysis. Importantly, because 
of the nature of this protocol the second read in each pair is complementary to 
the original mRNA and therefore indicates what DNA strand was transcribed. 
 
4.2.3 Sequence Alignment  
 
Sequence alignment was performed using the Tuxedo pipeline: Bowtie2 
(Bowtie2/2.0.2) and Tophat2 (TopHat/2.0.4)47. We supplied TopHat with the set 
of transcript models annotated in the Homo sapiens Ensembl database version 
69. The option fr-firststrand was used for the strand specific RNASeq libraries 
while all other parameters were used with default values. When provided with 
ssRNASeq data TopHat2 annotates aligned reads with the tag XS indicating the 
strand of origin in the DNA. 
 
4.2.4 Transcript summarization  
 
We used Ensembl v69 as the reference transcriptome to reconstruct the 
longest annotation for each gene based on the transcript and exon information 
provided by this assembly. We only included transcript isoforms that satisfied the 
following criteria: gene and transcript biotypes were annotated with the same 
type; transcript isoform annotation level was manual or automatic followed by 
manual revision (annotation levels 1 or 2) and transcript isoform was not reported 





is retained_intron, to be experimentally confirmed, or disruptive_domain).  
Moreover, each transcript isoform used for our gene models was annotated with 
their “isoform expression rank” across the tissue cohorts, and their support level 
(tsl) provided by the Genecode project. Tsl equal to 1 indicates that all splice 
junctions of that transcript are supported by at least one non-suspect mRNA; any 
other number suggests that the transcript is supported by suspicious ESTs. 
These final gene models were used as the reference loci, or features, for 
downstream analysis. 
 
4.2.5 Strand specific expression 
  
The final gene models in the summarized transcriptome obtained in 4.2.4 
were used to compute strand specific expression. Paired-end reads mapping to 
the forward or opposite strand of a feature were counted in order to quantify the 
raw amount of forward and reverse transcription on a particular locus.  In order to 
determine what DNA strand a read pair was originated from, we first used the 
reads’ XS tag, provided by TopHat2, to identify the strand for each read in the 
pair. Then, we use the fact that in our ssRNASeq protocol the second read is 
complementary to original mRNA and therefore the second read has to be on the 
same strand than the feature, while the first read on the opposite strand. These 
criteria unambiguously define a read pair DNA strand of origin.  
 
We discard all pairs in which one or both reads map to multiple locations 
in the genome, and all read pairs in which any of the reads was improperly 
mapped or did not have the XS flag provided by TopHat2 to indicate the strand of 
origin. 
 






Read counts normalization was performed using DESeq52, which models 
the read counts data using a negative binominal distribution and estimates the 
variance by modeling the sum of the shot or Poisson noise and the sample-to-
sample variation. DESeq first estimates the effective library size, and then divide 
the counts by the effective library size in order to bring counts into a common 
scale. Given the size of our cohort, we used the following parameters to estimate 
the variance (dispersion): method="per-condition", sharingMode="gene-est-only", 
fitType="local". Normalized counts were used for all other downstream analysis. 
 
4.2.7 ssRNASeq strand specificity estimation 
 
ssRNASeq protocol’s strand specificity is defined as the number or reads 
mapping to known transcribed regions at the expected strand. Assuming that 
most genes are transcribed in the sense direction, Levin et al., (2010) measured 
the strand specificity or protocol error rate of a library, as the fraction of reads 
mapped to the opposite strand generated by the forward gene. This fraction 
constitutes a measure of the protocol error rate, ranging from 0.5 for the best 
method to 12% for the less specific one24.  
 
In order to determine the protocol error rate, we select loci that do not 
overlap any other transcripts in our reference transcriptome, and do not have any 
other neighboring gene within 20Kb in either side (3’ or 5’ ends). We reason that 
the fraction of reads mapped to the opposite strand of those loci would constitute 
an estimate of our ssRNASeq protocol error rate (pe). The average pe in our 
cohort of 376 samples is 0.64% (min=0.17%, max=0.69%, sd=0.0055), 
demonstrating the high strand specificity of our libraries. 
 






In order to determine how many loci consistently express both forward and 
reverse strands, we first determined for each sample the protocol error rate as 
describe above as an estimate of the background noise in the opposite strand of 
a particular loci. For each sample, loci with read counts in both the forward and 
reverse strands, and opposite strand ratio (OPSratio= Reverse read 
counts/(Forward read counts + R read counts)) greater than the pe for the 
sample were considered as expressing both strands. Next, we leveraged the size 
of our full cohort (n=376) aiming at identifying those loci that are expressing both 
strands consistently across multiple samples. We reason that recurrent 
expression is an indicator of genuine transcripts; therefore antisense transcript 
expressed above the protocol error rate in different samples across the cohort 
would have a higher chance of being genuine. We defined a locus as having 
measurable antisense expression if that locus has OPSratio > pe in at least 5% 
(n=20) of the cohort samples. 
  
4.2.9 Antisense loci identification  
 
We used a probabilistic method for natural antisense transcripts 
identification using RNASeq (NASTI-seq178). That method incorporates the 
protocol error rate (pe) of the ssRNASeq procedure and employs a model 
comparison framework to identify loci with significant antisense expression. 
Briefly, for each locus in a reference transcriptome the method first calculates the 
probability of the observed read count data under a sense only model, in which it 
is assumed that the sense gene is the only one being expressed and the reads 
mapped to the opposite strand are due to the pe. Then, the method calculates 
the probability of the observed data under a second model, antisense model, in 
which the reads mapping to the opposite strand of a particular locus in the 
genome come from two different sources: pe and the bona fide expression of an 
antisense transcript overlapping the locus. The NASTIscore, a type of Bayesian 





data. Finally, a training dataset of true positives and true negative pairs was used 
to determine the minimum NASTIscore score that distinguishes between 
potentially true antisense loci from the background noise. 
 
We build the training datasets as follows. First, we determine all 
overlapping pairs in our reference transcriptome. Then, we annotated each pair 
according to the Ensembl gene biotype of the genes involved and the length of 
the overlapping regions. The true positive pairs dataset was conformed by all 
pairs of genes, with an exonic overlapping greater than one base pair and 
involving a protein coding gene and a known antisense transcript. The true 
negative dataset was conformed by all protein coding genes that do not overlap 
exons or introns of other genes, the closest neighboring gene in either direction 
is more than 20 Kb away and the mean number of reads mapping to the opposite 
strand of that gene is less than 50.  
 
4.2.10 Identification of lineage- and cancer-specific antisense loci 
 
We computed the NASTIscore for all loci with expression in both strands 
in at least one sample of a tissue cohort. The NASTIscore calculation was 
performed for each tissue type independently. Then loci with significant antisense 
expression, as determined by a NASTIscore greater than the minimum 
NASTIscore for each cohort (see 4.2.9), were aggregated. These loci will be 
denoted as antisense loci (ASloci) from here on. Furthermore, we defined three 
groups of antisense loci according to their presence in different cohorts. 
Antisense loci identified in all cohorts were termed ubiquitous ASloci, while 
ASloci identified in only one tissue type were name tissue or lineage specific. We 
also observed ASloci that were expressed in more than two tissue types but not 
in all and we treated this group as tissue enriched or non-specific ASloci. 
 Because our compendium is substantially enriched for cancer samples 





(LUAD) and squamous carcinoma (LUSC) patients, we identified lung cancer 
specific ASloci, that is, ASloci identified as such in the LUAD and LUSC tumor 
cohorts but not in the benign cohort. We further determined what ASloci were 
detected in our cohort of 31 lung cell lines and which ones were also identified in 
other cancers. The first of these groups correspond to lung cancer specific ASloci 
while the second one to cancer non-specific ASloci. 
 
4.2.11 Correlation between sense and antisense transcripts 
 
In order to determine the patterns of expression between genes of a cis-
NAT pair, we calculated different measures of correlation between the 
expression of the sense and antisense genes. The measures of correlation 
calculated were the Spearman correlation coefficient, the Pearson correlation 
coefficient, the coefficient of robust correlation and the mutual information. All 
these metrics produced very similar correlation results; therefore we chose the 
Spearman correlation for further analyses. The correlation was computed 
independently for each cis-NAT pair in each tissue cohort, as well as, across the 
combined cohort of 376 samples. The statistical significance of each correlation 
was corrected for multiple hypotheses testing using the Hochberg's procedure.  
We compute the null or random distribution, as the distribution of 
correlations between any two random genes. Similar to the cis-NAT calculation, 
we compute the null distribution for each tissue type and across our combined 
cohort.  
 
4.2.12 CpG islands analysis 
 
CpG islands have been found in 30 to 60% of unidirectional and 80% to 
95% of bidirectional promoters179. Bidirectional promoters refer to intergenic 
sequence between the transcription start sites of bidirectional genes pairs. 





arranged in head-to-head configuration and separated by less than 1000 bp180.  
Therefore, we used the presence or absence of CpG islands in a genomic region 
as proxy for the presence or absence of a gene promoter in that region.  
 
In order to determine whether overlapping regions of head-to-head cis-
NAT pairs harbor potential bidirectional promoters, we downloaded, from UCSC 
genome browser, tracks providing CpG island strength predictions, and mapping 
of bona fide CpG islands for the human genome hg19. These tracks are based 
on large-scale epigenome predictions described by 181.  Next, for each pair of cis-
NAT genes, we defined the DNA regions of overlap between those genes and 
then tabulated how many CpG islands are found within that overlapping region. 
We reason that if a gene promoter exists within the overlapping regions of cis-
NAT pairs, we should observe an enrichment of CpG islands in those regions. As 
a positive control we identified a set of bidirectional protein coding gene pairs 
using the definition presented above and including only gene pairs with gene 
expression correlation greater than 0.2 across our cohort of 376 samples. A 
mean correlation of 0.2 between the expressions of bidirectional genes was 
previously described180 and it is confirmed in by our own analyses. 
 
4.2.13 Differential expression analysis of sense/antisense pairs 
 
DESeq normalized read counts as described in 4.2.6 were used for 
differential expression analysis between lung adenocarcinoma and lung 
squamous tumor samples and their match normal samples. We reasoned that 
the forward and reverse expression of a particular locus could change in a 
consistent or inconsistent fashion between tumor and normal samples. In a 
consistent change, the expression of forward and opposite strands will be over or 
under expressed between tumor and normal samples. On the other hand in an 
inconsistent change, the expression of forward and reverse strands will change 





forward strand is over expressed the opposite strand will be under-expressed 
and vice versa, suggesting potential mechanisms of interference between sense 
and antisense genes.  
 
In order to identify loci with consistent or inconsistent changes in the 
expression of forward and reverse strands, we used a negative binomial test as 
described by Anders et al., (2010)52 to determine differential expressed cis-NAT 
pairs between tumor and normal samples. We first identified cis-NAT pairs for 
which both sense and antisense genes were differentially expressed with 
adjusted p-value <= 0.1. Then we defined a log fold change threshold (lfcth) of 1 
and select as consistent pairs differentially expressed cis-NAT pairs for which the 
absolute log fold change expression of sense and antisense genes were >= lfcth. 
Inconsistent cis-NAT pairs were defined as differentially expressed pairs for 
which the log fold change expression of the sense gene was >= lfcth, while the 
expression of antisense gene <= -1* lfcth, or vice versa. 
 
4.3 Results 
4.3.1 Development of a bioinformatics analysis workflow for antisense 
transcript analysis 
 
Strand specific RNA paired sequencing (ssRNASeq) data from a 
compendium of 376 samples (303 tissue and 69 cell lines samples), representing 
both cancer and benign from 9 different tissue types recently generated for our 
laboratory, was used to develop a bioinformatics workflow for the analysis and 
characterization of antisense expression in human cancers (Figure 4.1, 
Methods).  
 
First, sequencing reads were mapped to the human genome (hg19, 
GRh37) using TopHat2 (TopHat/2.0.4)47. Then, a summarized transcriptome was 





exon information provided in the Ensembl.v69 assembly. Only high quality 
transcript isoforms were included, while problematic and miss-annotated 
transcripts were filtered out (see Methods). This procedure generated 42,129 
gene models. Second, these gene models were used as reference loci to 
compute the number of strand specific pair-end reads mapping to the forward or 
reverse strand of each locus; and then to calculate the expression level of each 
strand in that locus (see Methods). Loci expression was then normalized using 
DESeq52. Third, strand specificity was calculated for each library in order to 
determine the protocol error or background noise affecting our estimation of the 
expression coming from the opposite strand (see Methods). Fourth, loci 
consistently expressing both, forward and reverse, strands across our cohort 
were identified. Moreover, a locus that has OPSratio > pe in at least 5% (n=20) of 
the cohort samples (Methods) was considered as a locus with measurable 
antisense expression. Fifth, a probabilistic method was used for natural 
antisense transcripts identification using RNASeq (NASTI-seq178). This method 
accounts for the variable protocol error in order to identify loci with significant 



















Finally, we calculated the correlation between sense and antisense 
transcripts forming cis-NAT pairs and determined tissue specific, tissue-
enriched/non-specific, ubiquitous and cancer specific antisense loci. Taken 
together this bioinformatics pipeline nominates expressed antisense loci across 9 
different tissue types and establishes their pattern of expression. The pipeline 
further aggregates tumor suppressor and oncogenes with significant antisense 
expression in a single catalogue, oncoNATdb.  
 
4.3.2 Antisense expression is pervasive across the human transcriptome.  
 
Figure 4.4a and Figure 4.4b show that in any given locus most of the 
observed expression originates on the annotated or forward strand; the 
expression originating from the opposite or reverse strand is overall two to three 
orders of magnitude lower (median of reverse/forward = 0.001). Accurate 
quantification of strand-specific expression is further complicated by the 
ssRNASeq protocol error (pe)24. To address this, we calculated the protocol error 
for each of our samples and then determined the fraction of the transcriptome 
with measurable expression in the opposite strand. pe ranges from 0.5 for good 
ssRNASeq libraries to 12% for the less specific ones24. The average pe in our 
cohort of 376 samples is 0.64% (min=0.17%, max=0.69%, sd=0.0055), which 
indicates a high strand specificity of our libraries (Methods) and supports the use 
of these data for identifying loci harboring expression of both strands. We defined 
a locus as having measurable antisense expression if that locus has opposite 
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authors. Figure C.1b indicates that forward loci would represent 87% of 
transcripts, reverse loci 4%, and forward-reverse loci 9% respectively.  
 
Although useful as an initial assessment, thresholding approaches, which 
use the OPSratio or the minimum number of reads in the opposite strand176,184-
186, as the only criteria to determine antisense loci, can be affected by biological 
variation, library size differences and the efficiency of the strand specific libraries. 
Thus, these approaches introduce error into the identification of antisense loci. 
More importantly, these methods do not account for the generally two-orders-of-
magnitude lower expression of reverse strand compared to the forward strand 
(Figure 4.4) Therefore, using only the OPSratio likely underestimates the number 
of antisense loci; missing loci with significant antisense expression, especially in 
those cases in which the sense strand is expressed at intermediate or high 
levels.  
 
In order to overcome these limitations, we used a probabilistic method for 
natural antisense transcript’s identification using RNASeq (NASTI-seq178) that 
incorporates the variable pe of ssRNASeq protocols and employs a model 
comparison framework to identify loci with significant antisense expression 
(Methods). Briefly, for each locus in a reference transcriptome the method 
calculates both the probability of the observed read count data under a sense 
only model and an antisense model. In the first model, reads mapped to the 
opposite strand are due to the pe only, while in the second one reads mapping to 
the opposite strand of a particular locus come from two different sources: the pe 
and the bona fide expression of an antisense transcript overlapping the locus. 
Therefore, an antisense locus is defined as a region of DNA in which the 
antisense model explains better than the sense only model the read count data 
observed over that region (Methods). 
 
Out of all transcribed loci consistently expressing the reverse strand 
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4.3.4 Bidirectional promoters would direct the expression of head-to-head 
cis-NAT pairs 
 
As shown in Figure 4.8b, HTH cis-NAT pairs have the highest positive 
gene expression correlation and this expression pattern is observed across 
different tissues types, suggesting that a common structural mechanism 
coordinates the expression of both genes in the pair. Similarly, co-expression 
patterns have also been observed for divergent but not overlapping genes driven 
by bidirectional promoters180. Inspecting the structural properties of the HTH cis-
NAT pairs, we realized that close to 60% of those pairs involve overlapping 
regions between the 5’UTR (5UTR-5UTR) regions of each gene or the 5’UTR 
and the first exon (5UTR-exon, specially between protein coding and ncRNAs 
where UTRs are not defined).  Taken all these together, we hypothesize that 
HTH cis-NAT pairs may share bidirectional like promoters that direct the 
concerted expression of both genes in the pair. 
 
Bidirectional promoters are genomic regions that initiate transcription in 
both directions191. In metazoans, bidirectional promoters have typically been 
associated with the intergenic sequence between the transcription start sites of 
two non-overlapping genes arranged in divergent orientation and separated by 
less than a 1000 bp180. Recent studies have estimated that about 10% of protein-
coding genes would share a bidirectional promoter179. Bidirectional promoters are 
CG rich and CpG islands are present in 80% to >95% of bidirectional promoters, 
while only present in 30 to 60% of unidirectional promoters192. Other marks of 
active transcription such as RNA polymerase II occupancy and modified histones 
H3K4me2, H3K4me3, and H3K9ac have also been observed in bidirectional 
promoters179. Because of their high association with bidirectional promoters, we 
used the presence or absence of CpG islands in a genomic region as proxy for 
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(transcription start site associate RNAs) from the opposite strand154,193. 
Increasing evidence also suggests that these non-coding transcripts influence 
the expression of their cognate protein coding genes through multiple 
mechanisms that are still incompletely understood191. For NATs in particular, 
several examples of highly co-expressed HTH cic-NAT pairs have been reported 
in which the antisense gene regulates the expression of their sense counterpart. 
Sessa et al., 2007156 demonstrated that the expression of antisense transcripts to 
human HOXA genes promotes a collinear activation of the corresponding 
cognate HOXA sense genes. Extending these observations, Zhang et al., 
2009157 showed that HOTAIRM1, a non-coding RNA, was co-expressed with the 
HOXA gene locus and HOTAIRM1 positively regulated the expression levels of 
the HOXA gene. 
 
Our results give additional support to these observations regarding the 
pattern of expression of HOXA genes and their respective antisense genes 
(Figure 4.14a, Figure C.2). Moreover based on the similarities with those 
examples, both in the genomic structure and the high genes expression 
correlation, we illustrate several representative examples of other gene pairs in 
the HOXD (chr2), HOXC (chr12) and HOXB (chr17) clusters that exhibit similar 
co-expression patterns to the one described for the HOXA (chr7) cluster (Figure 
4.14b, Figure C.2a,b). These data suggests that a similar regulation mechanism 
between sense and antisense transcripts could exist in those other clusters.  
 
Importantly, these regulation patterns are not restricted to homeotic 
genes, as our results also nominate other known examples such as WT1/WT1-
AS (Figure 4.10a), as well as novel cis-NAT pairs with the characteristics 
described above and functions as diverse as cell adhesion and migration (BVES) 
(Figure 4.14b), Ras guanine nucleotide-releasing factors (RASGRF2) (Figure 
C.2c), transmembrane proteins (TMEM220, TMEM176B, TMEM176A) and 
transcription factors (NKX2-1, WT1, TBX5, HAND2, FOXD3) among others 
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BCL2L11 represent particular cases of the HTH cis-NAT pattern described 
before, while KRAS, PIK3CA and RAF1 correspond to tail-to-tail configurations. 
In these last cases, the transcription of a neighboring protein coding gene 
overlaps or runs into the 3UTR and the body of those oncogenes (Figure C.3).  
 
A second group of, an average, 2881 (sd=967.96) antisense loci were 
expressed at high levels in several tissue types and display low or absent 
expression in the others. These tissue enriched/non-specific antisense loci 
account for 26.21% - 53.23% out of all antisense loci identified in each cohort 
(Figure 4.16a). Protein coding genes in this group were enriched for cell 
adhesion, activation of protein kinases and embryonic morphogenesis (Figure 
4.16c, middle). Notably, 133 known cancer genes were also found in this 
category including AXL, MTUS1, E2F2, TET2, JAK2, STK11 MAP4K1, BCAS1 
and CCND1.  
 
Finally, we identified a third group of antisense loci that are mainly 
expressed at high levels in only one tissue type. We consider these to be 
lineage-specific (Figure 4.16b), with the possibility that such transcripts contribute 
to tissue specific processes. This category of transcripts represented the smallest 
group, with an average of 244 (sd=166) loci by tissue, representing only 1.8 - 7% 
out of all antisense loci identified in each cohort.  In contrast with the ubiquitous 
group, tissue specific antisense loci indeed were enriched for functions related 
with tissue development, morphogenesis and differentiation (Figure 4.16c, right. 
Out of 1563 linage specific loci, 113 involved tumor suppressors or oncogenes 
(Figure 4.16a) such as GTSE1, ERCC6 and GSK3B in LUAD; ABL2 in LUSC; 
ROS1, LCK and BCL2 in BRCA; TP53 and KLK10 in PRCA; CREBL2 and CDK2 
in PANC; and RET, ABL1, TBX1 and VAV1 in the lung cell lines (Figure 4.16a). 
By inspecting the coverage maps of these examples, we found that ROS1, RET, 
VAV1, ABL2 and BLC2 do not have annotated overlapping transcripts; however 
we observed clear evidence of embedded antisense transcription in all of them 
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4.3.6 Antisense loci in lung cancers 
 
Because our compendium is substantially enriched for cancer samples, and 
benign samples correspond only to match normal samples of lung cancer 
patients (lung adenocarcinoma (LUAD) and squamous carcinoma (LUSC)), we 
investigate lung cancer specific antisense loci. 2101 cancer-specific antisense 
loci were found expressed in LUAD or LUSC but not in the benign samples 
(Figure 4.17a); 1456 were expressed in both tissues and 1212 out of those were 
also found in our cohort of lung cell lines.  Out of those 1456 loci, 1260 were 
found in lung and at least another tissue type  (Figure 4.17a) whereas 196 were 
lung cancer specific (Figure 4.17b).  
Interrogating antisense loci involving cancer related genes, 88 cancer-
related genes were found in which the expression of the opposite strand was 
statistically significant according to the NASTIseq score. Interestingly several of 
those genes do not have a previously annotated antisense transcript; however 
our ssRNASeq data suggest the presence of promoter associated, intronic and 
3UTR antisense expression. E2F2 antisense transcript that locates to the 3UTR 
region of this gene has not been previously and is preferentially observed in lung 
cancers. ABL2, MTAP and GTSE1 display unannotated antisense expression 
originating from an embedded intronic transcript and they were mainly observed 
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adenocarcinoma or lung squamous carcinoma but not in lung normal samples. C) Tumor suppressors and 
oncogenes specific antisense loci. D) Functional analysis of all protein coding genes identified as cancer 
specific antisense sense loci. The heatmaps represent presence/absence of antisense the Antisense loci in 
a particular tissue type. 
 
Next, we focused on analyzing how the sense and antisense expression 
on a given locus changed between tumor and normal samples. We reasoned that 
the forward and reverse expression of a particular locus could change in a 
consistent or inconsistent fashion between tumor and normal samples. In a 
consistent change, the expression of forward and opposite strands will be over or 
under expressed between tumor and normal samples. In an inconsistent change, 
the expression of forward and reverse strands will change in opposite directions 
between tumor and normal samples. Therefore, when the forward strand is over 
expressed the opposite strand will be under-expressed and vice versa, 
suggesting different potential mechanisms of regulation between sense and 
antisense genes.  
 
In order to identify loci with consistent or inconsistent expression changes, 
we used DESeq normalized read counts over forward and reverse strand of a 
locus to perform differential expression analysis between tumor samples and 
normal samples (Methods). A negative binomial test52 was used to determine loci 
whose forward and reverse strands were differentially expressed. Both strands 
were required to have an absolute log fold change (lfc) greater than 1 with 
identical signs for consistent loci (lfc>=1 or lfc<=-1), while opposite signs for 
inconsistent loci (forward lfc>=1 and reverse lfc<=-1; or forward lfc<=-1 and 
reverse lfc>=1) (Methods).  
 
First an analysis of 3 pairs of matched LUAD tumor and normal samples 
was performed, revealing the four groups of loci that we hypothesized (Figure 
4.18a) and then this proof of concept analysis was extended to the full lung 
adenocarcinoma (n=66) and lung squamous carcinoma (n=36) cohorts. Figure 
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Table 4.4-2. Number of consistent and inconsistent differential expressed antisense loci.  
 LUAD LUSC 
 All Cancer-related All Cancer-related 
Consistent 
loci 
831 55 1258 71 
Inconsistent 
loci 
258 10 417 18 
 
Table 4.4-3. Break down by configuration of consistent and inconsistent differential expressed 
antisense loci.  
 LUAD LUSC 
 EMB HTH TTT EMB HTH TTT 
All cis-NAT 6807 1944 2152 6807 1944 2152 
Consistent 
loci 
125 133 65 171 131 84 
Inconsistent 
loci 
60 14 37 74 11 64 
Analyzing each tissue independently shows that HTH cis-NAT pairs are over-represented in consistent loci 
fisher test p-value=1e-5 and for both LUAD and LUSC 3x3 contingency table. Fisher test p-value<2.2e-16 
and 1.41e-15 for the 2x2 contingency table including the consistent loci. 
 
 
The Hypoxia-inducible factor 1-alpha (HIF1A) and the Tubulin 
Polymerization Promoting Protein (TPPP) are representative examples of 
consistent and inconsistent loci respectively. In the HIF1A locus the expression 
of forward and reverse strands increase in tumors samples with respect to 
normals (Figure 4.20a); while in the TPPP locus the expression of the antisense 
transcript increases in tumors while TPPP sense expression decreases Figure 
4.20b). Our data shows HIF1A and TPPP sense/antisense expression changes 
are rather general phenomena that is observed in both match tumor-normal pairs 
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4.3.7 oncoNATdb: a catalogue of antisense loci involving tumor 
suppressor and oncogenes 
 
Given the increasing evidence for the role of antisense dysregulation in 
cancer167-175,194, recent studies have suggested that targeting antisense 
transcripts in the clinical setting may represent a promising technology for 
modulating the expression of specific genes158,195. The first step in bringing these 
emerging therapies into the cancer arena is to catalogue and characterize all 
cancer related genes involved in cis-antisense regulation.  
We therefore created, oncoNATdb, the first catalogue of cis-NAT pairs 
involving cancer related genes. To do so, we first performed an unbiased search 
of cis-NAT pairs in which at least one of overlapping genes was a known tumor 
suppressor or oncogene and calculated the gene expression correlation for the 
cis-NAT pair across our combined cohort of 376 cancer samples. 51% of tumor 
suppressors and 46% of oncogenes were found overlapping with another gene in 
the opposite direction (Table 4.4-4). Given that 46% of other protein coding 
genes harbor overlapping transcripts, these data suggest that tumor suppressors 
are slightly enriched for overlapping antisense transcripts (Fisher exact test p-
value=0.0027), raising the possibility that antisense transcription could play a key 
role in modulating the expression of those genes.  
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Next, we focused in HTH cis-NAT pairs involving tumor suppressors or 
oncogenes that had evidence of bidirectional promoters, high gene expression 
correlation and statistically significant expression of the antisense strand (high 
NASTIscore). A representative list of these candidates is presented in Table 
4.4-5. Remarkably, our bioinformatics analyses capture the majority of cancer 
related genes known to be regulated by antisense transcripts. Furthermore our 
approach nominates new cis-NAT pairs involving tumor suppressors and 
oncogenes such as CCND2, MYCN, TP73, ATM and ETV7. An assessment of 
the mechanisms of regulation in these cis-NAT pairs will be informative for 
deciphering the role of antisense regulation in cancer.  
 
Then, we look for TTT cis-NAT pairs involving cancer related genes within 
the linage specific, tissue enriched, ubiquitous and cancer specific antisense loci 
groups described earlier. We observed known oncogenes such as KRAS, 
PIK3CA and RAF1, in which the transcription of a neighboring protein coding 
gene overlaps or runs into the 3’-UTR and body of those oncogenes. Moreover, 
we applied the same analysis for annotated EMB cis-NAT pairs involving cancer 
related genes and found cases such as HIF1A, a cancer specific antisense locus 
that changes consistently between tumor and normal samples, and NF1. A list of 
representative examples for these categories is presented in Table 4.4-6. 
Finally, we use our ssRNASeq data to directly examine the antisense 
expression on cancer related genes that did not have annotated overlapping 
transcripts. We found additional examples of oncogenes and tumor suppressors 
with significant expression of the antisense strand, suggesting potential novel 
transcripts that are overlapping and might regulate those genes. Such genes 
included RET, VAV1, E2F2, and BLC2. A representative list of those cases is 








In this study, we used strand specific RNA sequencing on a cohort of 376 
samples to describe the magnitude and patterns of antisense expression in the 
human cancer transcriptome. Based on our analyses, we have further created 
oncoNATdb, a catalogue of antisense loci involving tumor suppressor and 
oncogenes. Our results indicated that more than 60% of all human loci have 
measurable expression of the antisense strand, suggesting that antisense 
transcription is widespread phenomenon across the genome. In addition, we also 
show that, on average, 37% of those loci would correspond to bona fide 
expressed cis-NAT pairs (Figure 4.7). Our estimates expand upon earlier limited 
assessments of the extent of the antisense transcriptome86,87. 
 
Moreover, by analyzing the expression patterns of overlapping genes, we 
confirmed that gene expression of overlapping genes is positively correlated 
(median Spearman correlation coefficient R=0.27), and in particular, that HTH 
cis-NAT pairs have the highest correlation (median Spearman correlation 
coefficient R=0.4) among all other configurations types (Figure 4.8). This high 
correlation of HTH pairs, we hypothesize, is due to bidirectional promoters that 
direct the expression of both genes in the pair.  Supporting this, greater than 78% 
of HTH cis-NAT pairs have CpG islands in their overlapping regions, suggesting 
bidirectional promoters; similarly 83% of bidirectional but not overlapping genes 
had CpG islands in their intergenic regions (Figure 4.12).  This hypothesis is 
further supported by detailed analyses of known examples in the HOXA cluster 
and experimental validation of the co-expression pattern of novel candidates in a 
panel of lung cell lines (Figure 4.14, Figure 4.15). Remarkably, differentially 
expressed cis-NAT pairs between tumor and normal samples that exhibit a 
consistent behavior are enriched for HTH pairs (Table 4.4-3), implying a common 






Furthermore, by analyzing the expression of antisense loci in the major 
tissue types in our compendia, we observed three broad groups of loci according 
to the expression of their antisense strand across different tissue types. A first 
group of 3025 ubiquitously expressed antisense loci were found present in all 
tissue types in our cohort (Figure 4.16a). Those loci were enriched for functions 
such as DNA repair, phosphorylation and ncRNA processing. Notably we found 
116 cancer related genes such as Fli-1 Proto-Oncogene ETS-Transcription 
Factor (FLI1), which forms a HTH cis-NAT pair with FLI1-AS1 transcript, and 
KRAS, PIK3CA and RAF1 oncogenes that form TTT cis-NAT pairs with 
neighboring protein-coding genes. Although the potential functional 
consequences of such tail-to-tail configurations remain largely unknown, a recent 
study in gastric cancer showed that two TTT overlapping protein-coding genes 
could concordantly regulate each other by forming a RNA duplex at the 
overlapping 3’-UTRs which increased their mutually stability162. Our resource 
provides potential new candidates for this phenomenon, which merit further 
investigation and raise the exciting possibility of new avenues for regulating the 
expression of well-known oncogenes. 
 
 A second group of, on average, 2881 (sd=967.96) tissue enriched 
antisense loci expressed at high levels in several tissue types and absent in the 
others (Figure 4.16b) was also found. Within this group 133 cancer-related genes 
displayed significant antisense expression. The last group corresponds to lineage 
specific antisense loci that are mainly expressed in only one tissue type (Figure 
4.16b). Despite representing only 1.8 - 7% out of all antisense loci identified in 
each cohort, lineage specific antisense loci were enriched by tissue specific 
morphogenesis functions and thus have the potential of regulating biological 
processes unique to distinct tissue types. We found 113 cancer-related genes in 
this group, such as ROS1, ABL2, and BLC2. Interestingly, several of those genes 
do not have annotated overlapping transcripts, however our ssRNASeq shows 
clear evidence of embedded or promoter associated antisense transcription in all 





ssRNASeq to resolve the expression of complicated regions with overlapping 
transcripts and to discovered potential new loci with significant but unannotated 
antisense expression. 
 
In addition, comparing tumor and benign lung adenocarcinoma and 
squamous carcinoma samples we found cancer specific loci (Figure 4.17) and 
showed that the expression of the two genes in a cis-NAT pair can change in the 
same (consistent) or opposite (inconsistent) direction when comparing tumor and 
normal samples (Figure 4.18, Figure 4.19). Noteworthy examples of consistently 
regulated cancer related genes loci in LUAD were Zinc Finger E-Box Binding 
Homeobox 2 (ZEB2) and Polo-Like Kinase 4 (PLK4). ZEB2 and ZEB2-AS1 form 
a bidirectional HTH cis-NAT pair that is essential for down regulation of E-
cadherin during epithelial-mesenchymal transition. Beltran et al 2008196 elegantly 
showed that ZEB2 and ZEB2-AS1 transcription is directed by a bidirectional 
promoter and more importantly that ZEB2-AS1 up-regulates Zeb2 protein 
expression, which in turn down regulates E-cadherin expression. On the other 
hand PLK4 is essential for centriole duplication and when overexpressed is 
important in tumorigenesis by inducing centrosome aberrations. Notably, the 
antisense transcript overlapping PLK4 has not been annotated yet, but according 
to our ssRNASeq data it is oriented in a HTH configuration overlapping the 5 
prime region of PLK4. Elucidating the biological implications of those very 
different expression patterns would deepen our understanding of antisense 
regulation and their role in cancer. 
 
Finally, our study comprehensively examined, for the first time, the extent 
of antisense expression in cancer related genes and aggregated these findings in 
oncoNATdb, a catalogue of cancer-related genes with significant antisense 
expression. We show that 608 (50.08%, out of 1214) of cancer-related genes 
have annotated overlapping transcripts and 296 out of those 608 have significant 
antisense expression. 48.64% of the overlapping pairs formed by those 296 





of bidirectional promoters, whereas 25.02% are TTT and 24.34% are EMB gene 
pairs. In addition, 155 cancer-related genes have significant antisense 
expression, but do not have annotated overlapping transcripts. 27 out those 155 
have a very close gene nearby (<=500bp) whose UTRs transcription could 
extend into the neighboring gene. The reaming 128 cancer-related genes could 
have putative novel antisense transcripts.  
 
Antisense transcripts regulate several well-studied tumor suppressors and 
oncogenes and there is increasing evidence of antisense dysregulation in 
cancer167-175. The molecular mechanisms of this regulation are multiple and 
poorly understood. Nevertheless controlled modulation of natural antisense 
transcripts, in order to modify the expression of sense genes158, is an emerging 
technology that promises to deliver gene specific targeted therapies. 
 
This study characterizes the landscape of antisense expression in human 
cancers and provides a resource, oncoNATdb, which will enable cancer 
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Table 4.4-5. Representative tumor suppressors and oncogenes head-to-head cis-NAT pair with bidirectional promoters.  
The column Status indicates that, according to previous reports, the antisense transcript regulates the actionable gene expression. 












































































































































































































































































*HTH=Head-to-Head, TS=Tumor suppressor, ONC=Oncogene. All gene pairs in this table have had CpG islands in the overlapping regions between the 
























Table 4.4-6. Representative tumor suppressors and oncogenes tail-to-tail and embedded cis-NAT pair with bidirectional promoters.  
The column Status indicates that, according to previous reports, the antisense transcript regulates the actionable gene expression. 






















































































































Table 4.4-7. Representative tumor suppressors and oncogenes with significant antisense expression but no annotated overlapping transcripts. 
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Chapter 5  
Conclusions and future directions  
 
Omics technologies for high-throughput profiling of human genome, 
transcriptome and proteome are revolutionizing cancer research and nourishing 
a nascent paradigm in clinical care. The success of this new precision medicine 
paradigm will depend on our ability to combine diverse omics-based 
measurements to distill clinically relevant information that can be acted upon. 
This thesis developed bioinformatics approaches to integrate multi-omics 
datasets and applied these approaches in three distinct studies that identified 
novel actionable genes and pathways in cancer.    
 
 In Chapter 2, alternative targetable proteins were found in non-small cell 
lung cancers (NSCLC) with activating mutations in KRAS (a well-know but 
undruggable oncogene) by profiling their transcriptome, proteome and 
phosphoproteome. By reconstructing targetable networks associated with KRAS 
dependency, we nominated lymphocyte-specific protein tyrosine kinase (LCK) as 
a critical gene for cell proliferation in these samples, suggesting LCK as a novel 
druggable protein in KRAS-dependent NSCLC.  
 
In Chapter 3, novel oncogenic gene fusions were identified in NSCLC 
patients with previous to this work unknown driver genes. By characterizing the 
landscape of fusions in NSCLC, this study revealed that gene fusions incidence 
is an independent prognostic factor for poor outcome. It was also discovered that 





exclusively in patients with an unknown driver; resembling previously reported 
and targetable kinase fusions in lung cancers.  
 
Chapter 4 focused on the characterization of cancer-related genes that 
are involved in sense-antisense gene pairs and could be regulated by natural 
antisense transcripts. By determining the extent of antisense gene expression 
across human cancers and comparing with well-documented sense-antisense 
pairs, our results raise the possibility that antisense transcripts could modulate 
the expression of well-known tumor suppressors and oncogenes. This study 
provided a resource, oncoNATdb, a catalogue of cancer related genes with 
significant antisense transcription. The oncoNATdb catalogue will enable 
researchers to investigate the mechanisms of sense-antisense regulation and 
further advance our understanding of their role in cancer, which may lead to the 
discovery of novel therapies. 
 
Collaborative projects such as the Cancer Genome Atlas (TCGA) and the 
International Cancer Genome Consortium (ICGC) are generating vast amounts 
of omics-based datasets. These projects are profiling the genome, transcriptome 
and proteome for thousands of patients, providing an unprecedented molecular 
characterization of multiple cancer types. These datasets also provide an 
exceptional opportunity to discover novel targetable genes and pathways on 
patient populations with currently unmet needs. Integrative analyses would be 
essential to translate this molecular information into informative findings that 
points towards new therapies and novel targets. The bioinformatics methods 
presented in this thesis illustrated different approaches to integrate these multi-
omics datasets.  
 
In the future, I anticipate building scalable bioinformatics approaches 
based upon the computational methods presented in this thesis to integrate the 
multi-omics datasets produced by projects such as the TCGA and the ICGC. 





patient in the cohort (using all omics-based measurements), integrate relevant 
clinical information and determine patient communities based on those molecular 
and clinical profiles. As fundamental feature of this system should include a 
patient’s molecular profile oriented search, allowing researchers (and patients) to 
use a patient’s molecular profile in order to retrieve those other patients 
(community of patients) with molecular profiles that closely resemble the query. 
The community of patients generated by this “patients like me-molecular” search, 
may facilitate the discovery of novel targets and unappreciated therapeutic 
opportunities.  
 
The discovery of LCK kinase as druggable target in KRAS-dependent 
NSCLC merits additional experimental and bioinformatics studies to explore its 
specific role in these cancers and potential avenues to inhibit its activity. 
Preliminary results, not shown in this dissertation, indicate that LCK localizes to 
the nucleus of KRAS dependent cells. A previous report in T-acute lymphoblastic 
leukemia (T-ALL) also showed nuclear localization of LCK. In T-ALL LCK binds 
to the promoter of LIM domain only protein (Lmo2)197, which is a critical 
transcription factor in the development of this disease197. Therefore, LCK could 
be exerting unanticipated roles in KRAS dependent NSCLC by directly regulating 
the activity of transcription factors. In order to study this hypothesis, Chip-Seq 
experiments for LCK could be performed in order to determine what DNA regions 
LCK binds and identify the genes that are regulated, if any exists. Coupling those 
experiments with RNASeq or microarray profiling after LCK knockdown could 
also reveal the precise links between LCK and the apoptosis pathways that were 
suggested in chapter 2. In addition, it is essential to extend the clinical 
significance of LCK in disease free survival in order to determine the prognostic 
value of LCK in lung cancer. For this, we could use the currently available TCGA 
NSCLC dataset to evaluate the significance of LCK as a prognostic marker.  This 
analysis is, however, complicated by the overall poor prognosis of lung cancers, 
but we anticipate that detailed clinical follow-up of the TCGA and our internal 






The identification of low recurrence NRG1 fusions, as well as NRG1 
overexpression, in NSCLC driver negative patients suggest that close to 4% of 
NSCLC driver negative patients could benefit from further studies on the role of 
NRG1 in NSCLC and the development of directed therapies for targeting NRG1. 
Chemotherapy is the first line treatment for more than 50% of patients with 
NSCLC, regardless of the stage; however, in some cases chemotherapy cannot 
remove the tumor or prevent disease recurrence. A study recently published 
demonstrated that residual tumor cells after chemotherapy express high levels of 
NRG1; moreover, inhibition of NRG1 signaling significantly enhanced the 
magnitude and response to chemotherapy152. A deep characterization of all 
NRG1 fusions presented in this study (localization, and interaction partners), as 
well as the common signaling pathways activated in both fusion index samples 
and outlier expression samples would help to determine the mechanism of action 
of NRG1. Chapter 3 also presented a novel approach for identifying and filtering 
out the vast amount of false positive fusions produced by any of the fusion 
algorithms. The fusion classifier developed in chapter 3 could be further 
improved by including information about the presence or absence of an open 
reading frame (ORF) in the fusions formed. In order to include this, we would 
need to extend the algorithm to determine the sequence of all potential fusion 
transcripts formed between the 5’ and 3’ fusion genes and then determine the 
longest ORF that extends beyond the fusion breakpoint. A categorical value, 1/0, 
would then be included as an additional feature in the classification step. 
Including ORF information would focus the results on rearrangements producing 
fusion proteins, as the previously reported kinase fusions. Finally, the fusions 
database generated in this study could be extended to include additional lung 
datasets and additional fusion events called with improved fusion detection 
algorithms. This database could constitute a reference point for other 






Chapter 4 focused on the characterization of cancer-related genes that 
are involved in sense-antisense gene pairs and could be regulated by natural 
antisense transcripts. This is a very new field and the future directions are 
unlimited. To begin with, this study suggests a relationship between HTH-cis-
NAT pairs and bidirectional promoters, which could be further enhanced by 
integrating omics-based measurements of additional chromatin marks of histone 
modification and nucleosome free regions. Generating these datasets for the cell 
types used in this study is the only limiting factor to making progress in this 
direction. The ssRNASeq utilized in this study also confirms a widespread 
expression of antisense transcripts from the promoter of many genes as it was 
previously observed in yeast193. We have not address the extension of those 
specific type of ncRNAs, neither its relation with cancer genes. An immediate 
follow up study would characterize this phenomenon as preliminary observations 
of the coverage maps of gene expression shows that promoter ncRNA (paRNA) 
are highly transcribed from several cancer genes across tissue types. 
oncoNATdb could be further extended to include those examples of paRNA that 
have not been annotated but found in cancer-related genes. More importantly, 
the study presented in chapter 4 suggested that many cancer-related genes 
could be regulated for antisense transcripts. Therefore, designing clever 
experiments to disentangle the mechanism of regulation should be at the 
forefront of future follow up studies. In particular, it would be essential to 
demonstrate what antisense transcripts activate or silence their respective 
cognate gene targets. Stabilization of oncogenes mRNA may lead to increased 
activity in cancer cells, while interference in tumor suppressors expression may 
abolish their activity promoting cancer development.  
 
In conclusion, the computational methods for integrating omics-based 
datasets developed in this thesis will assist others with similar tasks and 
challenges. More importantly, these approaches nominated novel targetable 
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found only in the transcriptome dataset ( ~78%). Only 17% and 5% of the proteins would be found as 
differentially expressed in the proteomics or phospho-proteomics datasets respectively (A t-test adjusted 
pvalue <=0.05 for the LFC was used to select differentially expressed proteins). D) Average transcript 
expression of informative and non-informative genes across the panel of cell lines. Informative genes have a 
smaller dynamic range of expression than the non-informative genes. Whiskers correspond to the data point 
+/- 1.5 of the interquartile range of each box. The widths of the boxes are drawn proportional to the square-
roots of the number of genes in each group. E) Distribution of the differential expression values for 
informative (red) and non-informative (blue) genes when comparing KRAS-Dep vs KRAS-Ind cell lines. The 
longer tails in the distribution of non-informative genes determines the set of genes that are selected as 
differential expressed genes by a naïve approach leaving out most of the informative genes. F) Proteins 
found as differentially expressed only in the transcriptome dataset have very general and unspecific 
functions. Proteins in this dataset are mainly glicoproteins, transmembrane or secreted proteins, which are 
characterized by a wide dynamic range of expression but are not necessary related with KRAS dependency 
phenotype.  G) Proteins found as differentially expressed using the S score are enriched on very specific 
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A) KRAS knock down impairs proliferation in NSCLC KRA-DEP but not in KRAS-Ind cell lines. Two 
independent lentivirus shRNAs significantly decrease cell proliferation in KRAS-Dep cell lines but not in 
KRAS-Ind ones. The error bars correspond to the standard error calculated over three independent 
replicates. B) Inhibition of LCK using small molecule inhibitor (LCK Inhibitor II, Millipore, CAS 918870-43-6), 
preferentially impaired cell proliferation in KRAD-Dep (red) but not in KRAS-Ind cell lines (green). C) MET 
knock down impairs proliferation in NSCLC KRAS-Dep but not in KRAS-Ind cell lines mimicking the effect 
observed by KRAS knock down. The error bars correspond to the standard error calculated over three 
independent replicates. D) Inhibition of MET using small molecule inhibitor selectively, but mildly, decreases 
cell proliferation in KRAS-Dep (H441, H358) but not in KRAS-Ind (H460, H2122, A549) cell lines. E) 
Analysis of LCK staining with respect to patient overall survival. LCK positive samples = 11, LCK negative 
samples = 12. We observed the largest difference in survival probability between LCK-positive and LCK-
negative patients at 3 years after diagnosis. At this point in time, the survival probability of LKC positive 
samples (KRAS-Dep) is above 75% while only 50% for the LCK negative (KRAS-Ind) samples as shown in 
the figure below.  The Chi-square test p-value for the difference in the survival probability at 3 years is 
p=0.23. Moreover, the overall survival curves for LCK positive and LCK negative are not statistically 
significant over the full course of time (Chi-square test p= 0.379).  This is not surprising given the small 
number of samples available for the analysis, which translates in low power for detecting differences in 
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Table A-1 SPIA analysis on the differentially abundant proteins identified by the S score. Status A=Activated, I=Inhibited 
 
KEGG
ID Size NDE pNDE tA pPERT pG pGFdr pGFWER Status 
Tight junction 4530 121 8 7.4E-06 1.4E+01 2.3E-01 1.6E-04 7.5E-03 1.3E-02 A 
Epithelial cell signaling in bacterial 
infection
5120 63 6 1.3E-05 1.8E+01 2.8E-01 3.5E-04 7.5E-03 2.7E-02 A 
Focal adhesion 4510 193 10 4.6E-06 4.6E+00 9.1E-01 1.5E-02 7.7E-02 1.0E+00 A 
Thyroid cancer 5216 29 4 9.2E-05 2.3E+01 1.7E-01 4.3E-04 7.5E-03 3.3E-02 A 
Pathways in cancer 5200 312 9 1.2E-03 8.8E+01 5.2E-02 4.8E-04 7.5E-03 3.8E-02 A 
ARVC 5412 69 3 2.0E-02 1.2E+01 4.0E-03 4.3E-04 7.5E-03 3.4E-02 A 
Bacterial invasion of epithelial cells 5100 64 5 1.9E-04 1.6E+01 5.9E-01 9.4E-03 5.7E-02 7.4E-01 I 
Colorectal cancer 5210 61 3 1.4E-02 2.9E+01 1.3E-02 8.9E-04 1.1E-02 7.0E-02 A 
ECM-receptor interaction 4512 83 4 5.0E-03 2.0E+01 3.7E-02 1.0E-03 1.1E-02 8.0E-02 I 
Endometrial cancer 5213 51 4 8.4E-04 2.1E+01 4.1E-01 8.7E-03 5.6E-02 6.8E-01 A 
Osteoclast differentiation 4380 125 5 3.9E-03 2.8E+01 1.0E-01 2.8E-03 2.7E-02 2.2E-01 A 
Fc epsilon RI signaling pathway 4664 73 4 3.2E-03 3.6E+01 1.7E-01 4.5E-03 3.9E-02 3.5E-01 A 
Vascular smooth muscle contraction 4270 104 2 2.1E-01 5.8E+01 4.0E-03 7.4E-03 5.3E-02 5.8E-01 A 
Natural killer cell mediated cytotoxicity 4650 120 3 7.8E-02 1.1E+02 1.3E-02 5.0E-03 3.9E-02 3.9E-01 A 
Fc gamma R-mediated phagocytosis 4666 87 4 5.9E-03 2.6E+01 2.3E-01 1.0E-02 5.8E-02 8.2E-01 A 
ErbB signaling pathway 4012 83 4 5.0E-03 2.5E+01 3.9E-01 2.2E-02 9.9E-02 1.0E+00 A 
Wnt signaling pathway 4310 135 3 1.0E-01 2.5E+01 4.0E-02 1.6E-02 8.0E-02 1.0E+00 A 
Renal cell carcinoma 5211 70 2 1.2E-01 2.4E+01 5.2E-02 2.3E-02 9.9E-02 1.0E+00 A 



































































































section: Availability Notes 
X!Tandem The global proteome 




















































































Cell line KRAS_STATUS KRAS_MUT KRAS NRAS HRAS PIK3CA EGFR BRAF TP53 TP53_p.t 
SW900 KRAS_IND p.G12V,c.35G>T 1 0 0 0 0 0 0 1 
A549 KRAS_IND p.G12S,c.34G>A 1 0 0 0 0 0 0 0 
H460 KRAS_IND p.Q61H c.183A>T 1 0 0 1 0 0 0 0 
H2122 KRAS_IND p.G12C,c.34G>T 1 0 0 0 0 0 1 0 
SK-LU-1 KRAS_IND p.G12D,c.35G>A 1 0 0 0 0 0 1 0 
H1792 KRAS_IND p.G12C,c.34G>T 1 0 0 0 0 0 0 1 
H23 KRAS_IND p.G12C c.34G>T 1 0 0 0 0 0 1 0 
H1155 KRAS_IND p.Q61H,c.183A>T 1 0 0 0 0 0 1 0 
H1734 KRAS_DEP p.G13C,c.37G>T 1 0 0 0 0 0 1 0 
H2009 KRAS_DEP p.G12A,c.35G>C 1 0 0 0 0 0 1 0 
H358 KRAS_DEP p.G12C c.34G>T 1 0 0 0 0 0 0 0 
H441 KRAS_DEP p.G12V,c.35G>T 1 0 0 0 0 0 1 0 





Table A-4 TMA KRAS genotype and IHC pLCK staining. 






1 C004 12: GGT -> TGT Heterozygous WT Homozygous 1 
2 C006 12: GGT -> GAT Heterozygous WT Homozygous 1 
3 C008 12: GGT -> GAT Heterozygous WT Homozygous 1 
4 C016 12: GGT -> GTT Heterozygous WT Homozygous 1 
5 C026 12: GGT -> TGT Heterozygous WT Homozygous 1 
6 C035 12: GGT -> TGT Heterozygous WT Homozygous 1 
7 C038 12: GGT -> TGT Heterozygous WT Homozygous 1 
8 C045 12: GGT -> GTT Heterozygous WT Homozygous 1 
9 C046* WT Homozygous WT Homozygous 1 
10 C053 12: GGT -> GTT Heterozygous WT Homozygous 1 
11 C067 12: GGT -> GTT Homozygous WT Homozygous 1 
12 C087 12: GGT -> TGT Heterozygous WT Homozygous 1 
13 C112 12: GGT -> GAT Heterozygous WT Homozygous 1 
14 C113 13: GGC -> GAC Heterozygous WT Homozygous 1 
15 C116 12: GGT -> GAT Heterozygous WT Homozygous 1 
16 C117 WT Homozygous 34: G -> T Heterozygous 1 
17 C081 WT Homozygous 34: G -> T Heterozygous 1 
18 C083 12: GGT -> AGT Heterozygous WT Homozygous -1 
19 C082 12: GGT -> GTT Heterozygous WT Homozygous -1 
20 C037 12: GGT -> TGT Heterozygous WT Homozygous -1 
21 C071 12: GGT -> TGT Heterozygous WT Homozygous -1 



























23 C021 12: GGT -> GCT Heterozygous WT Homozygous -1 
24 C047 12: GGT -> TGT Heterozygous WT Homozygous -1 
25 C062 12: GGT -> TGT Heterozygous WT Homozygous -1 
26 C084 WT Homozygous 34: G -> T Heterozygous -1 
27 C033 WT Homozygous 35: G -> A Heterozygous -1 
28 C040 WT Homozygous 35: G -> C Heterozygous -1 
29 C058 WT Homozygous 34: G -> A Heterozygous -1 





Table A-5 Differentially activated pathways determined by the SPIA algorithm after knock down of LCK or MET. Status A=Activated, I= Inhibited. 
 
KEGGI
D Size NDE pNDE tA pPERT pG pGFdr pGFWER Status 
Rheumatoid arthritis 5323 90 16 1.4E-08 0.0E+00 1.0E+00 2.8E-07 1.4E-05 2.9E-05 I 
Amoebiasis 5146 104 13 1.9E-05 -3.2E+00 6.1E-01 1.4E-04 3.0E-03 1.5E-02 I 
Malaria 5144 51 8 1.5E-04 2.2E+00 3.3E-01 5.5E-04 8.3E-03 5.8E-02 A 
Lysosome 4142 119 13 7.9E-05 0.0E+00 1.0E+00 8.2E-04 1.1E-02 8.6E-02 I 
Natural killer cell mediated cytotoxicity 4650 122 8 3.5E-02 -8.9E+01 3.0E-03 1.1E-03 1.2E-02 1.1E-01 I 
NOD-like receptor signaling pathway 4621 53 7 1.1E-03 -8.1E+00 3.5E-01 3.6E-03 3.1E-02 3.8E-01 I 
Axon guidance 4360 127 10 6.0E-03 1.8E+01 7.5E-02 3.9E-03 3.1E-02 4.1E-01 A 
Vibrio cholerae infection 5110 53 6 5.6E-03 -4.6E+00 1.0E-01 4.8E-03 3.4E-02 5.0E-01 I 
Small cell lung cancer 5222 83 8 4.0E-03 -1.8E+01 1.8E-01 6.0E-03 3.7E-02 6.3E-01 I 
African trypanosomiasis 5143 32 5 2.8E-03 2.2E+00 4.8E-01 1.0E-02 5.8E-02 1.0E+00 A 
Antigen processing and presentation 4612 71 7 6.2E-03 -3.0E+00 3.7E-01 1.6E-02 8.4E-02 1.0E+00 I 
Bile secretion 4976 69 7 5.3E-03 -2.6E+00 3.0E-01 1.2E-02 6.5E-02 1.0E+00 I 
Toll-like receptor signaling pathway 4620 95 9 2.6E-03 1.6E+01 2.8E-01 6.0E-03 3.7E-02 6.3E-01 A 
 
Specific pathways associated with 
MET Knock down 
  
  
B cell receptor signaling pathway 4662 72 8 8.0E-04 -8.7E+00 3.5E-01 2.5E-03 4.3E-02 2.6E-01 I 
Renal cell carcinoma 5211 69 5 4.1E-02 -1.8E+01 1.3E-02 4.6E-03 5.2E-02 4.7E-01 I 
ErbB signaling pathway 4012 83 8 2.0E-03 -1.6E+01 3.9E-01 6.4E-03 6.5E-02 6.5E-01 I 
Focal adhesion 4510 192 12 7.1E-03 -2.6E+01 1.7E-01 9.3E-03 8.6E-02 9.5E-01 I 




































Table B-1.Fusions used as true positives for the random forest classifier.  


































































































H441 2 2 EIF2AK2 SULT6B1 umich 14 2 9 9 18 355 408 132 TD TRUE 
H1793 21 12 RUNX1 PTPRR umich 5 13 9 8 17 10 5 9 InterC TRUE 
H1734 17 17 MRC2 MAP3K3 umich 1 2 9 9 18 63 34 68 IntraC TRUE 
H1734 12 14 FAM60A DPF3 umich 6 8 9 9 18 268 18 1 InterC TRUE 
C057 9 6 DAPK1 GMDS umich 2 7 5 5 10 5 6 3 InterC TRUE 
C011 5 5 TTC1 DOCK2 umich 2 28 9 9 18 20 11 21 IntraC TRUE 
A63 9 19 TSC1 SMARCA4 umich 16 12 3 4 7 4 1 5 InterC TRUE 
A35 5 8 CD74 NRG1 umich 3 6 9 9 18 275 139 150 InterC TRUE 
A35 5 8 CD74 NRG1 umich 5 6 8 5 13 9 139 2 InterC TRUE 
A34 3 3 RAF1 TMEM40 umich 6 11 9 9 18 22 4 7 TD TRUE 
A25 5 5 SLC12A7 TERT umich 3 12 9 9 18 56 50 41 TD TRUE 
A25 9 20 CDK9 AHCY umich 5 9 2 3 5 3 7 7 InterC TRUE 
A25 9 20 CDK9 AHCY umich 3 9 1 1 2 1 7 1 InterC TRUE 
lc_s51 X X EDA MID1 seoul 1 7 8 8 16 9 1 3 IntraC NA 
lc_s48 4 6 SLC34A2 ROS1 seoul 13 12 9 9 18 390 35 203 InterC NA 





lc_s39 5 6 CD74 ROS1 seoul 3 10 9 9 18 440 19 372 InterC NA 
lc_s39 5 6 CD74 ROS1 seoul 3 9 2 2 4 3 19 2 InterC NA 
lc_s26 2 2 MAP4K3 PRKCE seoul 34 2 7 8 15 8 1 6 IntraC NA 
lc_s26 2 2 EML4 ALK seoul 13 10 9 9 18 27 4 30 IntraC NA 
lc_s20 17 17 BCAS3 MAP3K3 seoul 22 2 5 5 10 5 1 7 IntraC NA 
lc_s13 10 12 FGFR2 CIT seoul 2 25 9 9 18 25 5 23 InterC NA 
a8d6694
c-a213-
10 10 CCDC6 RET tcga 9 12 5 2 7 8 17 2 IntraC NA 
36bf02f8
-c1c8-
4 6 SLC34A2 ROS1 tcga 13 12 9 0 9 86 2 44 InterC NA 
028e99e
9-5b9a-
6 6 EZR ROS1 tcga 5 10 8 9 17 31 223 16 IntraC NA 






Table B-2 Comparison of the number of fusions among different tumor stages in LUAD.  




Stage II Stage III Stage IV 
Stage I  0.2937 0.7833 0.1472 
Stage II   0.2194 0.04902 
Stage III    0.2008 
 
Table B-3 Comparison of the number of fusions among different tumor stages in LUSC.  




Stage II Stage III Stage IV 
Stage I  0.01409 0.7258 0.09339 
Stage II   0.06015 0.01956 

















Table B-4 3’ Representative fusions recurrence across the combined cohort and in the driver positive and driver negative samples.  





















ROS1 6 0 5 0.857 0.000 1.295 700 314 386 
NRG1 3 0 3 0.429 0.000 0.777 700 314 386 
MAP3K3 2 0 1 0.286 0.000 0.259 700 314 386 
RET 2 0 2 0.286 0.000 0.518 700 314 386 
ALK 1 0 1 0.143 0.000 0.259 700 314 386 
TERT 1 1 0 0.143 0.318 0.000 700 314 386 
DZIP1 2 0 0 0.286 0.000 0.000 700 314 386 
WWOX 2 0 0 0.286 0.000 0.000 700 314 386 
ABCC5 2 0 2 0.286 0.000 0.518 700 314 386 
C1orf22
2
2 1 0 0.286 0.318 0.000 700 314 386 
LILRB2 2 1 1 0.286 0.318 0.259 700 314 386 
RABGAP
1L
2 0 0 0.286 0.000 0.000 700 314 386 
ZNF585
B
2 0 0 0.286 0.000 0.000 700 314 386 
AFF3 2 1 0 0.286 0.318 0.000 700 314 386 
PEMT 2 2 0 0.286 0.637 0.000 700 314 386 
FGFR3 2 0 2 0.286 0.000 0.518 700 314 386 







Table B-5 3’ Representative fusions recurrence across the combined cohort and in the driver positive and driver negative samples.  













SLC34A2 3 0.429 0.955 0.777 700 314 386 
MYH9 3 0.429 0.955 0.777 700 314 386 
TXNRD1 3 0.429 0.955 0.777 700 314 386 
GPR98 3 0.429 0.955 0.777 700 314 386 
DAPK1 2 0.286 0.637 0.518 700 314 386 
CD74 2 0.286 0.637 0.518 700 314 386 
RAF1 2 0.286 0.637 0.518 700 314 386 
SLC12A7 2 0.286 0.637 0.518 700 314 386 
CCDC6 2 0.286 0.637 0.518 700 314 386 
UCHL5 2 0.286 0.637 0.518 700 314 386 
PPP1CC 2 0.286 0.637 0.518 700 314 386 
FOXK2 2 0.286 0.637 0.518 700 314 386 
POLD3 2 0.286 0.637 0.518 700 314 386 
SAMD12 2 0.286 0.637 0.518 700 314 386 
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Table C-1 Comparison of gene expression correlation distribution for different configurations.  
The head-to-head configuration is the one with highest correlation among all other ones. Student t-test p-









Tail-to-Tail  1 0.9999 2.73E-272 
Head-to-
Head 
1.23E-144  4.16E-42 0 
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